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Epidemiological studies suggest that cannabis is a risk factor for psychotic illness. 
The main active ingredient is Δ-9-Tetrahydrocannabinol (THC). In healthy humans, 
the acute administration of THC can elicit transient psychotic symptoms and 
cognitive impairment. THC stimulates the endocannabinoid CB1 receptor (CB1R). 
However, beyond CB1Rs, the mechanism underlying the pro-psychotic effects of 
THC is unknown. The exploration of candidate mechanisms was the first major theme 
in this thesis. In Study 1 the pro-psychotic properties of intravenous (IV) THC were 
confirmed. Thereafter, studies 2 and 3 explored whether the pro-psychotic effects 
were related to excess striatal dopamine release or abnormal neural oscillations 
respectively. 
 
The cannabis plant contains over sixty cannabinoid molecules, one of which, 
Cannabidiol (CBD) can antagonise some of the pharmacological effects of THC. It 
has been suggested that the absence of CBD in modern, ‘high-potency’ forms of 
cannabis (sinsemilla or ‘skunk’) underlies the risk of such preparations for mental 
health. However the evidence for this is sparse. Characterising the effect of CBD on 
THC-elicited responses was the second major theme in this thesis. Studies 4 and 5 
tested whether CBD inhibited acute THC elicited psychosis. 
 
 
In study 1 the psychotomimetic effects of acute IV THC were confirmed. THC-
elicited positive symptoms were distinct from anxiety, and negative symptoms were 
distinct from sedation. Cognitive performance was impaired under THC conditions. In 
study 2, THC had no significant effect on striatal dopamine release despite inducing 
robust positive psychotic symptoms. In study 3, THC-elicited positive psychotic 
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symptoms were related to reduced bi-frontal coherence in the theta (4-8Hz) band. 
Studies 4 and 5 both showed that CBD pre-treatment inhibits acute THC-elicited 
psychosis. 
 
Overall two major findings emerged. 1. The pro-psychotic effects of THC were 
related to abnormal neural oscillations, but not to striatal dopamine release; and 2. 





In general psychosis refers to the presence of hallucinations (false perceptions), 
delusions (false, fixed ideas, which carry overwhelming significance for the patient) 
and thought disorder. For over 100 years the psychoses have been divided into 
organic and functional categories.  
 
Organic denotes an identifiable systemic or central pathology. Organic psychoses can 
be secondary to endocrine disorders (thyroid disease); metabolic disease (acute 
intermittent porphyria); autoimmune disorders (paraneoplastic limbic encephalitis); 
infection (herpes simplex encephalitis); seizures (temporal lobe epilepsy); space-
occupying lesions; stroke; head-injury; demyelinating diseases (metachromatic 
leukodystrophy); neurodegenerative disease (Lewy-body dementia); basal ganglia 
disorders (Wilson’s disease); nutritional deficiencies (B12 deficiency); medications 
(acyclovir); environmental toxins (thallium); and psychoactive drugs (LSD).  
 
The identification of an organic psychosis depends upon a thorough history, physical 
examination and the prudent use of laboratory investigations. Identification of an 
organic cause of the psychosis can dramatically change the subsequent management 
and prognosis.  
 
Functional psychoses are diagnoses of exclusion (i.e. exclusion of identifiable organic 
pathology). There are as yet no diagnostic tests. Diagnosis is made of clinical grounds 
(symptoms/signs) according to the criteria in the Diagnostic & Statistical Manual of 
the American Psychiatric Association (APA, DSM-IV-TR) or the International 
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Classification of Diseases of the World Health Organisation (WHO, ICD-10). The 
two classification systems are broadly similar. They subdivide the functional 
psychoses into schizophrenia (paranoid type, disorganised/hebephrenic type, 
catatonic, undifferentiated, residual [and simple in ICD-10]); persistent delusional 
disorders, schizophreniform disorder (DSM-IV-TR), brief psychotic disorders and 
schizoaffective disorder. Psychotic symptoms can also occur in bipolar disorder and 
major depressive disorder.  
 
For a DSM-IV-TR diagnosis of schizophrenia, the following criteria must be met: 1. 
The presence of characteristic symptoms [at least two, (or one if delusions are bizarre/ 
or if auditory hallucinations form a running commentary or discuss the patient.)] for 
most of the time for one month (or less if treated), which can be delusions, 
hallucinations, disorganised speech, grossly disorganised behaviour or negative 
symptoms (blunted affect, alogia or avolition). 2. Social or occupational dysfunction. 
3. Continuous signs of disturbance for six months (including one month of psychotic 
symptoms). Caveats are that the symptoms cannot be secondary to a mood disorder, a 
pervasive developmental disorder, or as a result of an identifiable organic illness. 
 
Schizophrenia has a global lifetime prevalence of 0.3-0.7%1. Family, twin and 
adoption studies have shown that the vulnerability for schizophrenia is partly genetic, 
with heritability estimated at approx. 80%, but the molecular genetics of 
schizophrenia remains unresolved1. A small proportion of cases can be explained by 
rare copy number variations (CNV’s)2. In addition numerous risk alleles have been 
proposed, the evidence being strongest for disrupted in schizophrenia-1 (DISC1) and 
neuregulin-1 (NRG1)3, 4. That many of the candidate genes are associated with other 
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neuropsychiatric syndromes, such as epilepsy and autism, serves to highlight the 
deficiencies in our current systems of classification5. Environmental factors which 
have been shown to confer risk for schizophrenia are; early life adversity, growing up 
in an urban environment, minority group position and cannabis use6. An influential 
view, which has stimulated much research, is that schizophrenia is a 
neurodevelopmental disorder, which arises from the interaction between risk genes 
and environmental risk factors1.  
 
In schizophrenia the most effective intervention is treatment with dopamine D2 
receptor antagonist drugs1. Such drugs (“neuroleptics”, “anti-psychotics”) are 
particularly helpful for hallucinations, delusions and agitation – although they do little 
for the negative symptoms. The efficacy of the first drug, chlorpromazine was 
discovered by chance in 1951-52. The efficacy of haloperidol was discovered by 
design [see below] in 1958. Numerous attempts have been made to discover drugs 
based on alternative mechanisms, in an attempt to avoid the Parkinsonian side effects 
of the D2 antagonists and to extend efficacy to the negative and cognitive symptoms7. 
Newer agents such as olanzapine and quetiapine (“atypical anti-psychotics”, “second 
generation anti-psychotics, SGAs”) are largely devoid of Parkonsonian effects, but 
their efficacy is still based on D2 antagonism1.  
 
Of the ‘atypicals’ only clozapine has demonstrable efficacy against negative 
symptoms, but the basis for this remains unknown, and side-effects limit it’s 
widespread use8. Although atypicals such as risperidone and olanzapine have become 
the first-line treatment, recent studies have cast doubt on whether they offer a 
significant advantage over the older drugs9. Instead of motor side effects, the 
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clinician’s concern is that the atypicals are associated with obesity, dyslipidaemia and 




Drug Models of Psychosis 
 
Several drug classes are said to be psychoto-mimetic. These are the stimulants 
(amphetamine/cocaine), the psychedelics (LSD), the NMDA-channel blockers 
(ketamine) and the cannabinoids (THC), amongst others. At one time or another, 
representatives of each class have been advanced as ‘drug-models’ of endogenous 
psychotic illness10.  
 
Whatever the substance, the following argument has been used to support the 
usefulness of the drug-model psychosis: Since on the surface, the psychological 
manifestations of the drug induced psychosis and the illness are sufficiently similar, 
then their organic bases might also be akin. Thus, knowing about the mechanisms of 
the drug may inform about the, hitherto unknown, organic basis of endogenous 
mental illness. Drug-models have also been prominent in the discovery of medications 
for psychosis/schizophrenia11. 
 
This approach has been remarkably successful in the case of the amphetamine/cocaine 
model; the model itself becoming one of the main pillars of the Dopamine Hypothesis 
– now in its 3rd version, and arguably as ‘dominant’ within psychiatry as at any other 
time in the past half-century. A high-point of the dopamine-school was the 
recognition of schizophrenia–like psychoses in professional cyclists who abused 
amphetamine, and the realisation that a drug which blocked the effects of 
amphetamine in animals could be beneficial for endogenous psychotic illness12.  This 
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reasoning led to the discovery of haloperidol (subsequently identified as a potent 
dopamine D2 receptor antagonist), which swiftly translated to the psychiatric clinic. 
Haloperidol, and medications like it, completely changed the landscape of psychiatric 
practice12. 
 
With this success, a similar endeavour was attempted with the LSD-model psychosis. 
Drugs which block the effects of LSD in animals were quickly discovered (latterly 
shown to be serotonin 5HT2 antagonists), however such compounds turned out to be 
ineffective against the core symptoms of schizophrenia10. This gave weight to the 
well-known argument that the effects of LSD were, in any case, quite unlike 
endogenous psychosis, the former being characterised by visual experiences, the latter 
by pathological experiences in the auditory domain10.  
 
The origins of the ketamine-model and the glutamate-school go back to the 1960s.  It 
was realised that ketamine (and the related molecule, phencyclidine) could elicit 
profound changes in thinking and behaviour13. Such molecules (shown in the 1980’s 
to be NMDA channel blockers) were said to mimic not only the positive symptoms of 
schizophrenia, but the negative symptoms as well, and ‘explanations’ of endogenous 
psychosis based on glutamate emerged as a rival to the dopamine hypothesis. As was 
the case for dopamine, there has been considerable effort to identify schizophrenia-
related pathology in the glutamate system, usually focussed on receptor numbers or 
concentrations of glutamate in the brain14. There has also been a hope that a glutamate 
drug would prove beneficial against the core symptoms of schizophrenia, translate to 
the clinic, and in doing so - validate the model. Unfortunately, and similar to the case 
with the serotonin-model, this has not yet occurred [but see Patil et al 2007 Nat Med 
13:1102-7]15.   
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The Cannabinoid Model Psychosis 
 
The final class to consider, and the subject of this thesis, is the cannabinoid-model 
psychosis. From the perspective of the current day, cannabis is the prototypical drug-
model psychosis. For example, the world’s first known pharmacopoeia, the Pên-ts'ao 
(The Herbal), compiled in the first century AD, documents, rather succinctly; 
“Medical cannabis - stop eating. Eat more - you will see white ghosts.  And eat long-
enough - you will know how to talk with the gods” (1234AD edition).  
 
In 1840s Paris, many of the leading painters and writers of the day met as the Club de 
Hashischins and ingested what were described as large quantities of the drug. Their 
founding member, Jacques-Joseph Moreau Du Tours (1804-1884), a psychiatrist from 
the Bicêtre considered that “Hashish gives to whoever submits to its influence the 
power to study in himself the mental disorders that characterise insanity, or at least 
the intellectual modifications that are the beginning of all forms of mental illness”.  
The insight that a drug-model could be useful for exploring endogenous mental illness 
probably originates with Moreau Du Tours. His awareness of the links between 
“intellectual modifications” and mental illness was especially prescient, and such 
links are now commonplace in modern psychiatric thinking16. 
 
From the 1950’s until the 1970’s, there were occasional reports confirming that acute 
THC and cannabis could elicit transient psychotic-like phenomena17-21. Interest in 
central cannabinoid pharmacology was marginal however, until two streams of 
knowledge began to attract attention within their respective fields. In neuroscience it 
was becoming clear that the recently discovered endocannabinoids were transmitter-
like signalling molecules (which functioned as mediators of specific forms of synaptic 
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plasticity)22-26. In psychiatry there were more and more reports of a link between 





Modern cannabinoid research stems from elucidation of the structure of THC by 
Raphael Mechoulam and colleagues in the 1960s29. THC elicits psychological effects 
via partial agonism at the CB1 receptor, first identified in 198830 and cloned in 
199031.  The CB2 receptor was initially discovered in macrophages23 and was initially 
designated as the “peripheral cannabinoid receptor” or the “immune cell cannabinoid 
receptor”32. However recent evidence indicates that the CB2 receptor is expressed on 
activated microglia in the CNS, and probably on some neurons32, 33.  
 
Endogenous Ligands 
As for opiate research two decades earlier, the discovery of cannabis receptors 
prompted a search for endogenous agonists and surprisingly the endocannabinoids 
(eCBs) turned out to be lipids. The first eCB, N-arachidonoylethanolamide (AEA) 
was termed Anandamide, from the Sanskrit word Ananda, signifying “bliss”24. A 
second eCB, 2-arachidonoylglycerol (2-AG) was discovered in 199525, 34, and others 
followed. To date AEA and 2-AG have been studied most intensively. Other putative 
endocannabinoids include 2-arachidonyl glyceryl ether (noladin ether)35 and O-
arachidonylethanolamine (virodhamine)36.  Unlike conventional 
neurotransmitters/modulators, eCBs are not stored in vesicles, but synthesized ‘on 
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demand’ from membrane phospholipids37, 38. 
Retrograde Signals 
In 2001, an eCB was identified as the long-sought retrograde mediator underlying the 
electrophysiological phenomenon known as depolarising induced suppression of 
inhibition (DSI)22. Endocannabinoids act as retrograde signals at CNS synapses37-39. 
They are synthesized in dendrites but act presynaptically to inhibit the release of fast-
acting amino-acid neurotransmitters. (Thus ‘neurochemical information’ passes in a 
retrograde direction; from dendritic spines → axon terminal). Ultrastructural analyses 
have located key enzymes for eCB synthesis at dendritic spines, and have detected 
CB1 receptors on the terminals of neighbouring GABA- and glutamatergic neurons40-
42. In the CNS the CB1 receptor is a coupled to Gi/o-type G-proteins, which mediate 
inhibitory effects at pre-synaptic terminals. The short-term suppression of transmitter 
release is via inhibition of voltage-gated Ca2+ channels43 and activation of K+ channels 
whereas long-term inhibition depends upon 2nd messengers (inhibition of adenylate 
cyclase) and inhibition of the vesicular fusion process44, 45.  
In the neo-cortex, striatum and hippocampus, CB1R expression is considerably higher 
on GABAergic than glutamatergic terminals40, 46-48. The reason for this, and whether 
this pattern is seen throughout the CNS, remains unknown. Endocannabinoids are 
synthesized by principal output neurons such as Purkinje cells in the cerebellum, 
pyramidal neurons in the hippocampus and cortex, medium spiny neurons in the 
striatum, and dopaminergic neurons in the midbrain49. By releasing 
endocannabinoids, principal neurons are able to regulate their excitatory and 
inhibitory inputs. Retrograde endocannabinoid transmission constitutes another layer 




Endocannabinoids have emerged as essential mediators of several forms of transient 
(5-30s) and long-term (>1 hr) plasticity in the cortex, limbic system, basal ganglia and 
cerebellum22, 26, 50-53. So far in all cases, eCB-dependent plasticity is expressed pre-
synaptically as a decreased probability of neurotransmitter release.  At the behavioural 
level, intact eCB signalling is required for cerebellar-dependent motor learning54 and 
for extinction of aversive memories in the amygdala55. At CA3-CA1 synapses in the 
hippocampus, eCBs appear to facilitate memory encoding. Activity-driven synthesis 
of 2-AG in dendritic spines of pyramidal neurons leads to long-term depression of 
neighbouring GABA and cholecystokinin (CCK) terminals, so that adjacent excitatory 
synapses are primed for strengthening by reducing their threshold for long-term 
potentiation (LTP)56 (Box 1A). Endocannabinoids also mediate a novel form of 
plasticity called, spike-timing-dependent-LTD26.  
Recent research indicates that endocannabinoid-mediated synaptic plasticity is likely 
to employ 2-AG as the retrograde signal57.  The synthesis of 2-AG is driven by the 
stimulation of type I metabotropic glutamate receptors and Ca2+ entry via voltage 
operated channels, which activate the synthetic enzyme sn-1 diacylglycerol lipase 
(DAGL-α) (Box 1A). Genetic inactivation of DAGL-1α fully eliminates all form of 
endocannabinoid-mediated plasticity in the cortex, the hippocampus, the striatum and 
the cerebellum57. In contrast to the subtle effects of 2-AG, acute administration of 
exogenous cannabinoids markedly disrupts neuronal signalling and circuit dynamics 
(Box 1B). Consequently, THC and other exogenous CB1 receptor agonists decrease 
synchronised neuronal firing in the hippocampus and inhibit theta oscillations58, 
LTP59, and at the behavioural level, impair learning and memory.  
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Box 1 The Molecularneuropharmacology of cannabinoids 
 
A) In area CA1 of the hippocampus, pyramidal neurons synthesize and release  
the endocannabinoid, 2-
arachadonoylglycerol (2-AG); 
which acts at CB1 receptors on 
adjacent nerve terminals. 
Synthesis of 2-AG is driven by 
stimulation of metabotropic 
glutamate receptors (mGlu1) 
or by Ca2+entry via voltage-
operated channels.  
Compelling pharmacological 
evidence indicates the 
existence of an, as yet 
uncharacterised, eCB bi-
directional transporter (T?).  
Consistent with a retrograde 
mode of action, the synthetic 
enzyme sn-1 diacylglycerol 
lipase (DAGL) is localised in 
dendritic spines, whilst  
2-AG undergoes catabolism 
by monoacylglycerol lipase 
(MAGL) in pre-synaptic terminals. 
 
Endocannabinoid dependent plasticity is expressed pre-synaptically as a, transient (5-30s) or 
prolonged (>1h), reduction in neurotransmitter release. Compared to excitatory terminals, 
GABA/CCK terminals in the hippocampus express more CB1 receptors and are more sensitive to 
cannabinoids. In CA1, it has been shown that locally released 2-AG depresses GABA-ergic 
inhibition, thereby facilitating long-term potentiation (LTP) at adjacent glutamatergic  
excitatory synapses. CB1 receptors on glutamatergic terminals might serve to limit the extent of  







B) Exogenous cannabinoids such 
as Δ9-tetrahydrocannibinol 
(THC) disrupt rather than mimic 
the subtleties of the eCB system 
in the hippocampus. THC 
inhibits long-term-potentiation of 
CA3-CA1 synapses and impairs 




receptor; DAG, diacylglycerol; 
Gi/o and Gq, G-proteins; IP3, 
inositol triphosphate; NMDA, N-
methyl D-aspartate receptor; 
PIP2, phosphatidylinositol (4,5)-
bisphosphate; PLC-β, 




Plant Derived Cannabinoids 
 
Cannabis sativa contains over 60 different phytocannabinoids, of which only THC, 
cannabidiol (CBD) and Δ-9-tetrahydrocannabivarin (THCV) have been studied in any 
detail60. Unsurprisingly most research has focussed on THC, given it’s dramatic effect 
on the human psyche.  
 
Δ-9-Tetrahydrocannabinol 
THC elicits a number of pharmacological effects, which are dependent upon dose. In 
some cases, responses can be biphasic. For instance in rodents and dogs relatively low 
doses of THC can stimulate motor activity, whereas high doses can induce catalepsy61  
Similarly, low doses of THC tend to be associated with an anxiolytic effect in animal 
models, whereas high doses can be anxiogenic62. Finally, in animal models, low doses 
of THC can elicit conditioned-place preference (CPP, a marker of ‘addiction’) 
whereas higher doses elicit aversion63.  
The pharmacology of THC covers a plethora of responses, some of which are 
therapeutically useful and others detrimental or unwanted. In the category of 
detrimental effects, it is well established that THC can impair short-term memory (the 
ability to register and recollect information)61, and working memory/executive 
function (the ability to hold and manipulate information on-line)64. Acute psychosis, 
anxiety and panic can occur following THC61. 
Beneficial effects include analgesia, which probably stem from the expression of 
cannabinoid receptors in peripheral nerve fibres, dorsal roots, the spinal dorsal horn 
and the peri-aquaductal grey65, 66.  Remarkably, existing analgesics such as 
acetominophen (paracetamol), appear to act via the endocannabinoid system57.  For 
example, the CB1 receptor antagonist SR141716A (Rimonabant), completely 
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abolishes the analgesic activity of paracetamol67. THC also has anti-inflammatory 
properties68. 
 
THC and other CB1 agonists can stimulate appetite and food intake69, probably via 
CB1 receptors in the hypothalamus and the modulation of appetite mediators such as 
ghrelin, leptin and peptide YY (PYY)70. Sold as Marinol (Solvay Pharmaceuticals), 
THC has been approved by the U.S Food & Drug Administration (FDA) for the 
treatment of anorexia in AIDS patients. The license also covers the use of Marinol as 
an anti-emetic in patients undergoing chemotherapy. 
Many patients suffering from multiple sclerosis (MS) patients report that their 
symptoms respond to cannabis. This prompted Baker and colleagues to investigate the 
efficacy of THC (and other CB1 agonists) in an animal model of MS. They found that 
CB1 agonists ameliorated the tremor and spasticity in diseased mice71.  This line of 
reasoning was developed and a cannabis extract sold as Sativex (GW 
Pharmaceuticals) containing THC and CBD in a 1:1 ratio, delivered by oromucosal 
spray, has now been licensed in the UK for the treatment of severe spasticity in 
multiple sclerosis. Contraindications are a personal or family history of psychosis or 
other severe psychiatric disorder.  
 
Cannabidiol 
Cannabidiol lacks the dramatic effects on the psyche that are associated with THC72. 
In stark contrast there has been interest in CBD as a possible anti-psychotic and 
anxiolytic medication73. Animal work in the 1970’s showed that CBD had anti-
convulsive properties72. Safety and tolerability were established, permitting a trial in 
patients with refractory temporal lobe seizures, and positive outcomes were 
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reported74.  Since the early 1980’s there have been reports that CBD ameliorates 
anxiety in animal models72 and recent human work suggests that CBD may be 
effective in social phobia75.  
CBD displays the signature of an anti-psychotic molecule in of animal models. To 
date it has been reported that CBD has efficacy across the standard models, involving 
the administration of apomorphine76, amphetamine77 or NMDA-channel-blockers78. 
Similar to clozapine, (but not haloperidol) CBD achieves this without eliciting motor 
side-effects (catalepsy)72. Experimental studies in man have also shown that CBD 
blocks the pro-psychotic effects of L-DOPA79. The first trial of CBD in schizophrenic 
patients reported equal efficacy with the established anti-psychotic amisulpride. 
Further work and confirmation is required however as numbers were small (i.e. the 
study was underpowered to detect a difference between CBD and the comparator) and 
the follow-up period, (4 weeks) was relatively short80. 
The receptor pharmacology of CBD remains enigmatic. Despite low affinity for the 
CB1 and CB2 receptors, low doses of CBD can antagonise cellular and tissue 
responses to CB1/CB2 agonists81. A plethora of receptor/enzymatic mechanisms have 
been reported for CBD including: antagonism of the orphan receptor GPR55, 
inhibition of adenosine re-uptake, inhibition of the cellular uptake and metabolism of 
anandamide, modulation of immune mediators and agonism at 5-HT1A receptors81. 
 
THC & CBD in cannabis products 
It is unique that a plant should harbour a component which appears to be pro-
psychotic (THC) as well as a molecule with putative anti-psychotic properties (CBD). 
Most cannabis work in the context of psychosis/schizophrenia has focussed on THC, 
and the apparent rise in THC content found in sinsemilla [skunk], which is cultivated 
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indoors by high intensity methods. But some have suggested that CBD content may 
be an additional factor in determining the psychotogenicity of an individual cannabis 
strain82. Some evidence to support this came from South Africa where there was a 
cluster of acute psychotic presentations to emergency departments in people smoking 
a strain of cannabis which lacked CBD83. In broad agreement, experimental work 
from a Brazilian group in the early 1980’s showed that CBD could antagonise the 
anxiogenic properties of THC.  
It is well documented that the THC content in illicit cannabis products has increased. 
Work by Potter and by King in the UK indicates that modern products arising from 
indoor cultivation of selective strains contain approximately 3x as much THC by 
weight, compared to traditional products84. Whereas THC content has increased, CBD 
appears to have decreased markedly, and is often undetectable in illicit products. 
Sinsemilla or skunk (high THC content: low CBD content) is now believed to 
dominate the UK cannabis market, and Potter’s work in particular provides strong 
evidence that this is the case84. If it is true that CBD antagonises the psychotomimetic 
properties of THC, then the lack of CBD in sinsemilla has implications for mental 
health in the community. 
 
 
Cannabis and Schizophrenia. 
 
 
The first link between cannabis and schizophrenia emerged in 1987 from a 
longitudinal study of over 45,000 Swedish conscripts. It was found that men who had 
smoked cannabis by the age of conscription had double the risk of schizophrenia in 
the ensuing 15 years85. (Individuals who had smoked cannabis on at least 50 
occasions by recruitment were 6x more likely to develop schizophrenia within 15-
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years). In 2002 a further analysis of the Swedish data (now involving over 50,000 
subjects), ruled out the possibility that the association was due to other psychoactive 
drugs86. Another seven cohort or general-population studies have reported similar 
findings, and have been extensively reviewed28, 87, 88.  
The association between cannabis and psychosis is now generally accepted, given the 
consistency of findings from numerous epidemiological surveys. Overall, meta-
analysis suggests that cannabis use increases the odds of developing a psychotic 
disorder by ~ x228. Although the consistency between studies is in keeping with a 
causal effect of cannabis on psychotic disorder, other non-causal explanations are 
feasible – specifically; confounding and reverse causation (“The self-medication” 
hypothesis”)89. The seven population studies outlined above made attempts to adjust 
for potential confounders such as stimulant use or childhood adversity, and found that 
associations between cannabis use and psychosis persisted, although the strength of 
the association typically decreased. However it is feasible that there are residual 
confounders, which were not accounted for. There is little evidence to support an 
explanation based on reverse causality, as most of the longitudinal studies excluded 
subjects with psychotic symptoms at baseline, or adjusted for symptoms at baseline89.  
Of course, the vast majority of people who use cannabis do not go on to develop a 
psychotic disorder, and there has been considerable interest in identifying which 
factors confer vulnerability. This effort has been underpinned by the conceptualisation 
of clinical psychosis/schizophrenia as a complex disorder, in which a constellation of 
risk-factors (environmental, genetic) interact to determine outcome, similar to the case 
with coronary heart disease for example. Amongst putative vulnerability factors, age 
of cannabis use onset (earlier = higher risk) has received empirical support90. There is 
also evidence suggesting that a history of trauma in childhood is a vulnerability 
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factor; Three studies found that the presence of childhood trauma and cannabis 
increased the risk over and above that posed by either factor in isolation91-93. 
Regarding vulnerability genes, an influential paper reported an interaction between a 
functional single nucleotide polymorphism in catechol-o-methyltransferase (COMT) 
and cannabis use, in conferring risk for psychosis94. An experimental study provided 
broad support95 but a subsequent epidemiological study did not find an interaction. 
More consistent evidence has emerged to support an interaction between cannabis use 




THC & Acute Psychosis 
In the last decade D’Souza and colleagues conducted a number of studies in which 
THC was administered to volunteers by the intravenous (IV) route. Using instruments 
designed for rating schizophrenic patients, it was found that THC (2.5mg or 5mg) 
could evoke time-limited positive psychotic symptoms and negative symptoms in 
otherwise healthy participants98. THC was also given to stable, medicated 
schizophrenic patients, which led to an acute exacerbation of psychotic symptoms in 
75-80% of cases99. In healthy participants (and patients), cognitive performance was 
poorer under THC conditions, and impairments were said to be similar to the 
cognitive deficits in schizophrenia. 
 
Psychoactive Drugs: Mechanism(s) of Action 
 
The majority of psychoactive drugs recognise and bind to specific receptors on the 
surface of CNS neurons, and this is the case for THC. Drug binding stabilises the 
receptor protein in a particular conformation, which provokes a change in the neuron. 
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Typically, the binding process alters an internal signalling cascade or changes the 
electrical properties of the neuron100.  
 
Over the past 75 years, pharmacology has succeeded in characterising the components 
of such events at increasingly exquisite levels of detail: Receptors have been isolated, 
cloned, sequenced and re-engineered. Insight has accumulated about their 3-
dimensional structure, their dynamics and how they are regulated within the cell. The 
same is also true of the components which make up the various downstream, 
intracellular signalling cascades, the ion-channels responsible for electrical signalling, 
and the uptake proteins which clear endogenous neurotransmitters from the synaptic 
cleft. 
  
And yet our knowledge of how psychoactive drugs (of any class) elicit their effects on 
the mind and behaviour remains partial. Moving beyond the nanoscale - (the small-
world of receptors and channels), and the micro-scale (the world of dendritic spines, 
synaptic boutons and individual neurons) - to the level of circuits, both local and long-
range, the certainty of our knowledge diminishes rapidly. Only when we approach the 
level of the mind/behaviour does confidence in our statements return, and we talk 
about a drug being an anxiolytic or a sedative for example. The gulf is between events 
at the small-world scale and events at the level of the mind/behaviour, specifically in 
the area that describes the organisation and dynamics of neuronal ensembles/ circuits.  
It is self-evident that a complete account of the mechanism of action for any 
psychoactive drug necessitates detail at all levels. 
 
To make this clearer, contrast this situation with an example from peripheral (non-
CNS) pharmacology. Atropine elicits tachycardia. In this case, there is a consistent 
 26
and complete explanation, which covers all levels of organisation, proceeding from 
the nano-scale (competitive antagonism of cholinergic M2 receptors on the surface of 
atrial pacemaker cells, leading to the suppression of inhibitory trans-membrane 
potassium currents and swifter depolarisation), to the micro-scale (individual cells 
within the pacemaker reach their firing-threshold earlier and discharge action-
potentials more frequently) to the scale of local circuits (cells making up the 
pacemaker population synchronise their action-potentials at a faster rate) and finally 
to the global scale (transfer of excitation through the conductive and contractile tissue 
of the heart at a higher frequency)101. 
In contrast, in the CNS, it can be difficult to know where a drug acts to produce a 
specific psychological/behavioural effect. This is particularly true for drug-effects on 
ubiquitous, distributed systems, and the endocannabinoids fall into this category. 
Thankfully some psychological/behavioural effects are less challenging. For instance, 
if a drug inhibits fear conditioning, a wealth of evidence would direct investigations to 
synapses within the basolateral amygdaloid nuclei102. A drug effect on episodic 
memory would direct us to the hippocampal complex58. In the case of drug-elicited 
psychosis, the task is more difficult. Some of the reasons for this are outlined briefly, 
not to renounce the possibility of ever understanding the neurobiology of psychosis 
(drug-elicited or otherwise), but to bring the difficulties into the open.  Before then 
however, it is important to clarify what is meant by the term “psychosis”. 
 
At the level of the mind, what is meant by “psychosis”?  
 
Our modern understanding of psychosis was shaped by German academic psychiatry 
in the early 20th century. Both the DSM and ICD classification systems are structured 
according to the ideas of Karl Jaspers (1883-1969) and other leading figures from the 
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‘Heidelberg school’ of psychiatry. Influenced by continental philosophy (Husserl in 
particular), Jaspers adapted the phenomenological method for the psychiatric clinic. 
Phenomenology aims at clear, unambiguous descriptions of subjective experience, 
(devoid of theoretical ‘baggage’). Jaspers’ method involved entering the mindset of 
the patient, in as open, non-judgemental and impartial a manner as possible, whilst 
prioritising the forms through which consciousness manifests (e.g perception, ideas, 
will) over any over particular details about the content103.  
 
Psychotic ‘symptoms’ include hallucinations (the perception of objects which do not 
exist in reality, via any of the sensory channels), and delusions (demonstrably false 
ideas held with an unshakeable conviction, which fundamentally re-orientate one’s 
way of being in the world). A third form of psychotic symptom is less easily reduced 
to a disorder of perception or a disorder of ideation. These are the ipseity disturbances 
(“ipse”- self), in which the basic, taken-for-granted distinction between an internal 
self and the external world is blurred: Some patients have the experience that their 
own thoughts are no longer private, or perhaps that their thinking, will, movement or 
emotions are under the direct control of an external agency. The term “breakdown of 
ego boundaries” is sometimes used as a shorthand for this type of symptom104 (2.1). 
 
 
The organic basis of psychosis, (drug-elicited or otherwise) 
 
A longstanding issue is whether the various psychotic experiences can be explained 
by neurological events at a single anatomical locus, given that psychosis can ‘reveal 
itself’ in an array of forms: via perception (the input-channels), thinking, the 
emotional mind, the sense of self (the ego), and the output-channels (movement and 
speech) 105. In Husserlian terms ‘psychosis’ is not an ‘essence’, ‘beyond which one 
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can make no further reductions’, but [too] readily splits into ‘purer’ phenomena. 
Therefore, does it make sense to ‘localise’ psychosis [a mixture of forms] to a single 




Nevertheless over time, various brain regions have been proposed to be fundamental 
in psychosis/(schizophrenia), including the hippocampus106, the thalamus107, the pre-
frontal cortices108, the higher auditory cortices109, the ventral-striatum/limbic-
striatum/associational-striatum110, and the ventral-tegmental area/A10 dopamine cell 
group111. By necessity in any single locus account, the candidate region/structure 
would be required to be involved in the processing of diverse mental forms, ideas as 
well as perceptions for example. A locus might then be better described as a ‘hub’. 
Whatever the terminology, the apparent problem of accommodating diverse mental 
forms within a single region/structure appears to disappear.  
 
Connectivity Hypotheses I 
 
Other accounts have assumed the importance of particular regions/structures but have 
also stressed the importance of connections [between CNS regions]. Within this 
category of hypothesis, the following have been highly influential; frontalÙtemporal 
‘disconnection’112; over-activity in the A10 dopamine -> ventral-striatal 
‘reward/reinforcement/salience’ pathways113 (Box 2 Classic studies); and ‘dysmetria’ 
in a distributed network involving the frontal cortices, thalamus and cerebellum114.  
 
Connectivity Hypotheses II 
 
A third family of hypothesis has become popular in the last few years. Here the spatial 
dimension, the issue of anatomical location, is less important. The critical factor is 
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time, specifically the organization of groups of neurons in time115, 116. To understand 
why they have become popular, it is necessary to take a [brief] detour into recent 
neurophysiology. We can set the stage by asserting that in health, the ‘normal’ 
operations of neuronal circuits/assemblies are the foundation of ‘normal’ conscious 
experience [perception, ideation, will and so forth]117-119 (A2.3).  Similarly, 
‘abnormal’ circuit/assembly operations are the foundation of ‘abnormal conscious 
experience [hallucinations, delusions, ipseity disturbance etc.] 115, 116, 120.  It has been 
proposed that the content of conscious experience [regardless of form] arises from the 
synchronous firing of individual neurons, either locally [at the sub-millimeter level] or 
across regions [centimeter level]121-123. Synchronicity ‘requires’ a metronome, (a 
tempo, a ‘clock’), and it appears that the CNS utilizes neural oscillations (rhythms) 
for this purpose124 (A2.4). 
 
From about 1993 onwards, rhythms in the theta, gamma and other frequency bands 
became more than just ‘markers’ of particular stages of sleep -there was a paradigm 
shift in neurophysiology. Terms such as ‘binding-by-synchrony’ and ‘coherence-in-
the gamma-band’ emerged as ‘explanations’ for perception, thinking, attention [even 
‘consciousness’ itself]118, 119 (A2.5). By the new millennium, it was realized that this 
list of higher faculties was exactly the same as those affected by major mental illness, 
and reports of ‘abnormal’ coherence/synchronicity/oscillations/rhythms in 
schizophrenia began to appear115, 116. Some have suggested that the rhythm 
disturbances in schizophrenia arise because of histopathology in a specific type of 






THC psychosis: Mechanism(s) 
 
The small world 
 
There is little doubt that THC psychosis begins with stimulation of central CB1 
receptors, since potent CB1 antagonists inhibit the central effects of THC126. The CB1 
receptor is found at high density in the prefrontal and association cortices, the 
anterior, mediodorsal, and intralaminar thalamic nuclei, the hippocampal complex, 
amygdala, entorhinal cortex, basal ganglia, substantia-nigra pars-reticulata, and 
cerebellum40, 127, 128.  
 
Exogenous CB1 agonists cannot be expected to mimic the subtleties of endogenous 
cannabinoid signalling such as spike-timing dependent LTD (A2.6). Endocannabinoid 
physiology is characterised by controlled local synthesis, release, uptake and swift 
metabolism27. So perhaps a safe assumption is that THC disrupts the normal 
functioning of the endocannabinoid system (in the same way that ketamine disrupts 
glutamate signalling or amphetamine alters monamines).  For example, given that the 
endocannabinoid system is involved in setting the strength of synaptic connections 
(hence: learning and memory), it is intuitive that the amnestic properties of THC stem 
from disruption of normal endocannabinoid physiology. 
 
The systems level 
Two candidate mechanisms have been proposed to account for the pro-psychotic 
effects of THC, excess striatal dopamine release27 and abnormal neural oscillations129, 
130.  
Dopamine has been at the heart of psychosis/schizophrenia for over forty years12, 
although interest waned (temporarily) in the early to mid 1990’s, with the rise of 
serotonin and glutamate-based accounts. But a study by Laruelle and colleagues in 
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1996 rekindled the dopamine hypothesis131. Using single-photon-emission-
tomography (SPET) it was shown that, compared to healthy controls, schizophrenic 
patients release greater amounts of dopamine into the striatum following the 
administration of IV amphetamine, and those patients showing the highest release 
experienced a transient relapse of psychotic symptoms (Box 2: Classic Studies).  
 
Here a similar methodology was applied for THC (study 2). It was hypothesised that 
THC would also induce excess striatal dopamine release and, in doing so, give rise to 
psychotic symptoms. The rationale was based on animal work. Cannabinoid CB1 
agonists increase dopamine cell firing, elicit burst-firing, and increase the release of 
dopamine at terminal fields in the striatum132-136. 
 
Animal work provided the rationale for study 3, the effect of THC on neural 
oscillations measured by electroencephalogram (EEG). Cannabinoid CB1 agonists 
have been shown to disrupt neural oscillations58, 129. Indeed CB1 agonists have 
become a useful tool, because they disrupt network synchrony without impinging on 
the firing rates of individual cells137. The assumption of course is that neural 
oscillations are important for ‘normal’ mental operations, but as outlined above (and 
in appendix 2.4) this assumption is not wholly devoid of experimental support. What 
is without any doubt however is that neural oscillations have an intimate relationship 



























































In the patient group, positive psychotic symptoms as rated by the PANSS 
increased following amphetamine (mean increase 3.0 points). The magnitude of 
positive symptoms was related to the extent of dopamine release (r2=0.3, 
p<0.001). Laruelle & Abi-Dargham (1999) J Psychopharmacology 13:358. 
A) Dopamine had long been 
associated with schizophrenia. In 
the 1990’s a series of intravenous 
amphetamine-challenge studies 
measured dopamine release, as 
indexed by the displacement of 
the D2-radiotracer [123I)IBZM. 
The major finding was that, post-
amphetamine, schizophrenic 
patients showed greater striatal 
dopamine release than healthy 
controls.  
B) Until recently EEG research meant 
event-related-potentials (ERP’s), in which 
the ‘real’ signal (the ERP) was extracted 
from the ‘noise’ by averaging many trials. 
But in 1989 there were the beginnings of a 
paradigm shift. Gray & Singer were 
studying electrical responses in the primary 
visual cortex of anaesthetised cats: but 
somewhat unusually they didn’t use patch 
or intracellular electrodes, the most 
‘refined’ methods of the day. Instead they 
measured the local field potential 
(equivalent to the EEG signal) as well as 
spiking behaviour (action-potentials) from 
numerous individual neurons.  
 
They found that visual stimuli (moving 
bars) evoked a burst of oscillatory activity 
and a burst of spikes. The ‘game-changing’ 
observation however, was that spikes 
(action-potentials) were phase locked to the 
trough of the oscillating (40Hz, gamma) 
rhythm (but not to the stimulus). 
 
In the ‘flood’ of papers that followed, a 
fundamental insight was that neurons 
reacting to distinct features of the same 
physical object synchronised their spikes 
with high precision.  
1. Field & Spikes 
respectively, at low temporal 
resolution. 
2. Field & Spikes 
respectively, at high 
temporal resolution. Gray & 





The effect of Cannabidiol on THC-elicited psychosis 
 
In stark contrast to THC, cannabidiol (CBD) is reported to have anti-psychotic 
properties in animal models and in schizophrenia73, 80. The relative concentration of 
CBD in modern ‘high-potency’ products (sinsemilla) is low84.  Some have speculated 
that the absence of CBD in sinsmilla endows this product with increased risks for 
mental health82. Laboratory studies are ideal for testing this idea, because pure 
cannabinoid preparations can be administered under controlled conditions. Hence, in 
study 4 (a pilot) and study 5, it was hypothesised that pre-treatment with CBD would 






































Since the 19th century there have been descriptions of acute schizophrenia-like 
positive psychotic symptoms in healthy subjects who had taken cannabis or been 
given THC16-19. The adverse effects of THC on memory are also well established. 
There remains controversy on whether cannabis mimics the negative symptoms of 
schizophrenia (e.g. loss of drive and motivation, reduced emotional expression, 
poverty of thought).  
 
Several studies have found that, amongst schizophrenic patients, the use of cannabis is 
associated with less negative symptomatology138-140 and one proposal is that patients 
self-medicate to alleviate negative symptoms138, 140. It has also been reported that 
cannabis-using healthy subjects exhibit less negative syndrome schizotypy compared 
to drug-free controls141, 142. Few laboratory studies have investigated the acute effects 
of cannabis/THC on the negative dimension. In contrast to the above, D’Souza and 
colleagues reported that IV THC increased negative symptoms in stable 
schizophrenic patients and in healthy controls98, 99. The authors did, however, 
acknowledge that the rating scale used may have been unable to distinguish true 




To confirm the pro-psychotic effects of THC, quantify the impact of THC on 
cognition and mood; and to explore if there are relationships between these primary 








The psychological properties of IV THC (2.5mg) were investigated in an 
experimental study utilising a within-subject, double-blind, placebo-controlled design. 
Participants attended 2 experimental sessions, at least 2 weeks apart, in which either 




Healthy male participants between 21 and 50 years who fulfilled entry criteria. 
Participants were asked to avoid alcohol and drugs for 24 hours before, and to abstain 
from driving for 24 hours after, experimental sessions. Participants were followed up 
by telephone the following day and a small monetary re-imbursement was made at the 
end of their involvement in the study. Participants (21-50) were required to have 
previously taken cannabis on at least one occasion; to score <15 on The General 
Health Questionnaire (GHQ-12)143; and be willing to provide written informed 
consent. Exclusion criteria were a history of mental illness, substance dependence 
(excluding nicotine), current or past severe medical disorders or a history of major 
mental illness in a first degree family member. Alcohol and drug dependence were 
excluded using the Michigan Alcohol Screening Test (MAST)144 and the Drug abuse 





Dronabinol (THC) was supplied by THC Pharm GmbH (Frankfurt am Main, 
Germany) and prepared as (1mg/ml) vials for intravenous injection by Bichsel 
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Laboratories, (Interlaken, Switzerland) according to the method of Naef and 
colleagues146. Placebo and active vials were identical in composition (except for 
THC) and identical in appearance. After dilution in normal saline, preparations for 
injection contained 2.5% (v/v) ethanol absolute. Previous studies of the effects of IV 
THC have utilized doses ranging from 2 to 5mg which approximate the levels of THC 





Psychological assessments and self-rated scales were administered at baseline (30 
minutes prior to injection) and at 30, 80 and 120 minutes following the final injected 





Instruments: The PANSS and the CAPE-state. 
 
 
THE PANSS (The positive & Negative Syndrome Scale)147 
The PANSS is a 42-item scale designed to measure the extent of psychotic symptoms 
in patients with schizophrenia. Items are rated (1-7). The 3-factor version includes a 
positive, negative and general dimension. 
 
The CAPE-state (Community Assessment of Psychic Experiences-state version) 
The CAPE-state is a validated 42-item self-reported questionnaire, derived from The 
Peters Delusions Inventory, which generates a positive, a negative and a depressive 
dimension score95. In the studies here the CAPE-state frequency score (0-never, 1-




Instrument: The UMACL  
 
 
The UMACL (University of Wales Mood Adjective Checklist)148 
Three dimensions of affect are measured - hedonic tone, energetic arousal and tense 
arousal (Matthews et al. 1990). It has been suggested that a 3-dimensional model of 
affect with separate pleasure-displeasure, awake-tiredness, and tension-relaxation 
dimensions provides a more informative description of core affect (compared to 1-
dimensional and 2-dimensional models) and fits better with experimental data148. For 
each dimension, subjects rated their level of agreement with four emotionally positive 
and four emotionally negative adjectives. The total score in each dimension was 
calculated by subtracting negatively valenced from positively valenced items. For 






Cognitive assessments began 10 minutes post-injection. The order of tests was 
consistent across both sessions (1. RAVLT-immediate recall, 2. Digit-span, 3. Verbal 
fluency, 4. RAVLT-20 min recall, 5 The N-back task, 6. The Baddeley reasoning 
task; Appendix 1). Cognitive testing was complete within 45 minutes post-injection.  
 
The Rey Auditory Verbal Learning Task (RAVLT) 
The standard administration format of the RAVLT was utilised. Immediate recall of a 
15-word list was assessed over 5 trials. Two different, but equivalent word lists were 




The Digit Span task evaluates the capacity of attention and working memory. 
Participants were tested in their immediate recall of a sequence of digits; and given 2 
attempts at each level of difficulty. In the reverse digit span condition, participants 
were required to recall the sequence in the reverse order. 
 
The N-Back task 
The n-back procedure has been used extensively to measure human working memory 
performance149. Participants were required to monitor a series of 20 standard playing 
cards for 2 seconds per card. They were required to recall both the suit and number of 
the card n-integers back, where n=0-2 (“0-2 back”), in three consecutive sessions with 
increasing level of difficulty. Responses were scored correct/incorrect, giving a 
maximum score of 20 for each level of difficulty. The task requires continuous 
updating of information stores in the 1-back and 2-back conditions. In contrast the 0-
back condition does not require manipulation of material in WM.  
 
The Baddeley Reasoning Task 
Participants were given 3 minutes in which to verify the truth of 32 logical statements 
containing 1 of 4 grammatical constructs such as; “B does not precede A….AB”. The 
highest obtainable score was 32. The Baddeley Reasoning Task evaluates the 









Blood (5mL) was collected at baseline and at 1, 5, 15, 30, 60 and 120 minutes post-
injection, and stored at -70ºC until analysis for [THC] and its major metabolites. The 
samples were extracted using solid phase extraction (SPE). Cannabinoids were 
derivatized and measured using gas chromatography with mass-spectrophotometric 





Data was assessed for normality using Kolmogorov-Smirnov test statistics. Because 
of absence of variance in positive psychotic scores under placebo conditions, 
Friedman’s Test, a non-parametric, repeated measures test was used to compare 
positive psychotic scores under THC and placebo conditions. Two-way repeated 
measures ANOVA was used to compare immediate recall in the RAVLT, with Trial 
(1-5) and Treatment (Placebo v THC) as within-subject factors. The Greenhouse-
Geisser corrected F-ratio was used because there was a violation of sphericity. For the 
remaining cognitive tasks and the UMACL, differences between placebo and THC 
were compared using paired t-tests. Relationships between normally-distributed 
variables were analysed using Pearson’s product moment correlation. Relationships 
between non-parametric variables were tested using Spearman’s rank correlation 











Of 24 volunteers, 22 attended both sessions. Participants were aged 28±6 years 
(mean±SD). Estimated lifetime exposure to cannabis ranged from 2 to ~1000 
episodes. Self-reported last previous use of cannabis ranged from 12 hours to 10 years 
(mean±SD: 2 years, 3.3 years). In urine drug screens, one participant tested positive 
for THC, but this was the case prior to both experimental sessions, thus data was 
included in the main analyses. No participants tested positive for other common drugs 
of abuse (opiates, cocaine, amphetamines, methamphetamine, methadone, 
benzodiazepenes) at either session. Of 22 participants, 3 subjects were unable to 
complete all parts of the protocol. One participant experienced nausea during the THC 
arm. Another participant refused to participate with cognitive testing or complete self-
rated scales under THC. Finally one participant experienced profound anxiety during 
the THC arm and requested ‘rescue medication’ (lorazepam 3mg) – and symptoms 
resolved completely within 30 minutes. Verbal reports of the IV THC experience are 




THC induced positive psychotic symptoms 
 
Scores on the PANSS positive subscale were increased from baseline following THC 
but not placebo administration (Friedman’s χ2=62, p<0.001). At 30 minutes post 
THC, PANSS positive scores had increased by a mean of 3.7 points (range 0-17), 
returning to baseline levels by 120 minutes (Figure 1.1). Similarly, subject-rated 
positive psychotic symptoms as measured by the CAPE-state increased from baseline 
following THC but not placebo (Friedman’s χ2=20, p=0.005). By 80 minutes post-
injection, CAPE-state scores had returned to baseline (Figure 1.1). Investigator-rated 
(PANSS) and subject rated (CAPE-state) positive psychotic scores at 30 and 80 
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minutes post-THC administration were correlated (Spearman’s rho=0.62, p<0.001). 
There was no relationship between positive psychotic symptoms, as measured by the 
PANSS and plasma concentrations of THC at 5 minutes, or 11-OH-THC 
concentrations at 5 minutes. Similarly, PANSS-positive scores following THC 
administration and AUC0-∞ were unrelated.  
Participants who had taken cannabis more often in the past [estimated number of 
episodes] were less likely to exhibit positive psychotic symptoms as rated by the 




THC induced negative symptoms 
 
Scores on the PANSS negative subscale were increased from baseline following THC 
but not placebo administration (Friedman’s χ2=30.1, p<0.001). ). At 30 minutes post 
THC, PANSS positive scores had increased from 7.0±0.0 (mean±SD) at baseline to a 
peak of 7.7±1.3. Scores on the CAPE negative dimension were increased from 
baseline following THC but not placebo administration (Friedman’s χ2=25.3, 
p=0.001). At 30 minutes post THC, CAPE negative scores had increased by a mean of 
4 points, returning to baseline levels by 120 minutes post-injection (Figure 1.2). There 
was no relationship between peak negative symptoms as rated by the CAPE and the 
PANSS. Peak changes in CAPE-negative scores were not related to plasma 









Box 3: Verbal Reports following IV THC 2.5mg 
 
 Participants’ verbal reports were recorded. Selected responses are included here.  
 
---------- 
“A feeling of great insight…I must write down this fantastic theory… of course 
 it’s all nothing”. 
 
“Every occurrence, cough, object, test, has deeper and connected meaning… 
All deliberate, planned…some sort of prank, to make a fool of people”. 
---------- 
 
“It was like you guys were having a conversation outside, saying…  
‘the dude in there is off his rocker’ ”. 
 
“It was threatening and sinister. I’m still a bit unsure of you. Your re-assurances 
 sound insincere”. 
 
“You know you were…[reading my mind]”. 
 




“…there was a dissociation between movement and the will to move”. 
 
“There seemed to be a disconnect between the original idea of moving and the actual 
instruction to move.”  
 
“It feels like my legs are being controlled by strings from the ceiling.  
Yes… actual strings.” 
 
“I felt I was so mad I would not have been surprised to find out 




“ There’s an incredible disconnection between thinking and saying something…” 
 
“ I wasn’t sure, after saying something if I had even been talking… I thought I had  
just thought the words but not said them”. 
 
“…The key theme in hallucinations…you do not realise if you are saying these words 
 out loud or just thinking it”. 
 
“It felt like my parietal lobe was talking. The thoughts would echo around the room”. 
 
---------- 







Intravenous Δ9-Tetrahydrocannabinol elicits positive psychotic symptoms 
SELF RATED POSITIVE 
PSYCHOTIC SYMPTOMS
TIME (mins)


























Figure 1.1. Following the administration of IV THC 2.5mg, healthy participants 
experienced positive psychotic symptoms (mean±s.e), whether rated by an external 
observer (The positive & negative syndrome scale [PANSS]; left panel) or according 
to scores on a self-rated scale (The community assessment of psychic experiences – 




Intravenous Δ9-Tetrahydrocannabinol elicits negative symptoms 





























Figure 1.2. Following the administration of IV THC 2.5mg, healthy participants 
experienced negative symptoms (mean±s.e), whether rated by an external observer 
(The positive & negative syndrome scale [PANSS]; left panel) or according to scores 
on a self-rated scale (The community assessment of psychic experiences – state 

































































IV THC elicited transient feelings of dysphoria. Under THC conditions, self-rated 
hedonic tone as measured by The UMACL, was decreased compared to placebo at 30-
minutes post injection (THC, mean=4.3, 95% CI= 2.9-5.8; placebo, mean=8.7, 95% 
CI= 7.3-10.1, t(17)=3.24, p=0.005) and at 80 minutes post-injection (THC, mean=7.2, 
95% CI= 6.3-8.1; placebo, mean=9.3, 95% CI=8.5-10.2, t(15)=2.62, p<0.05). By 120 
minutes there was no significant difference in hedonic tone between THC and placebo 






On the UMACL awake-tiredness dimension, THC induced feelings of tiredness at 30 
minutes (THC, mean=0.3, 95% CI= -1.8-2.4; placebo, mean=4.6, 95% CI= 3.3-5.8, 
t(17)=4.09, p=0.001), at 80 minutes (THC, mean= -1.0, 95% CI= -3.0-1.1; placebo, 
mean=5.5, 95% CI= 4.3-6.7, t(15)=4.74, p<0.000) and at 120 minutes post-injection 
(THC, mean= -0.2, 95% CI= -1.6-1.3 ; placebo, mean=5.1, 95% CI= 3.7-6.6, t(9)=, 
p<0.01) (Figure 1.3b). 
Notably, there was no relationship between changes in self-rated sedation and the 




On the UMACL tension-relaxation dimension, THC induced feelings of tense arousal 
at 30 minutes (THC, mean= -0.7, 95% CI= -3.2-1.9; placebo, mean= 
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 -7.3, 95% CI= -8.5-(-6.1), t(17)= -3.93, p=0.001) and at 80 minutes post-injection 
(THC, mean= -3.3, 95% CI= -5.7-(-1.0); placebo, mean= -8.3, 95% CI= -9.4-(-7.2), 
t(15)= -3.2, p<0.01). ). By 120 minutes there was no significant difference in tense 
arousal between THC and placebo conditions (Figure 1.3c).  
Notably, there was no relationship at 30 and 80 minutes post-injection between the 
degree of THC-elicited tense arousal and positive psychotic symptoms whether 
measured using the PANSS (Spearman’s rho=0.19, p=0.30) or the CAPE-state 
(Spearman’s rho=0.28, p=0.12). 
 





Immediate recall under THC or placebo conditions (Treatment) was compared in 
successive trials A1-A5 (Trial) of the RAVLT (Fig 1.4). There was an effect of 
Treatment, F(1, 19)=16.6, p<0.005, and an effect of Trial F(2.71, 51.49)=85.3, 
p<0.000, but no Treatment*Trial interaction F(3.04, 57.82)=2.24, p=0.09).  
Similarly, THC decreased performance in the forward (mean±SD: THC=7.0±1.2, 
placebo=7.8±0.9, t(18)=2.62, p<0.05) and reverse digit-span task (THC = 5.1±1.4, 
placebo= 6.2±1.1, t(18)=3.3, p<0.005) (Fig 1.5). Working memory deficits were 




There was a trend towards a difference in free recall (at 20 minutes post-encoding) 
between placebo (mean±SD: 11.1±3.3) and THC (9.7±3.5) conditions, t(17)=1.75, 
p=0.10 (Figure 1.4). Poorer episodic memory performance was related to higher 
PANSS positive scores (Spearman’s rho= -0.4, p<0.05). 
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Figure 1.3a Mean scores of hedonic 
tone as measured by the University of 
Wales Institute of Science & 
Technology mood adjective checklist 
(UMACL) following intravenous THC 









Figure 1.3b Mean scores of energetic 
arousal as measured by the University 
of Wales Institute of Science & 
Technology mood adjective checklist 
(UMACL) following intravenous 









Figure 1.3c Mean scores of tense 
arousal as measured by the University 
of Wales Institute of Science & 
Technology mood adjective checklist 
(UMACL) following intravenous 













THE EFFECT OF THC ON HEDONIC TONE
TIME (mins)

















THE EFFECT OF THC ON ENERGETIC AROUSAL
TIME (mins)




















THE EFFECT OF THC ON TENSE AROUSAL
TIME (mins)





















Participants showed no difference in performance between THC (mean±SD: 




Performance under THC or placebo conditions (Treatment) was compared in 
successive levels of difficulty (Level) in the N-Back task (Fig 1.7a). There was an 
effect of Treatment F(1, 17)=7.1, p<0.05 and an effect of Level F(1.33, 22.5)=130.1, 
p<0.001) but no Treatment*Level interaction.  Performance in the Baddeley reasoning 
task under THC (mean±SD: 22.3±7.6) was significantly poorer than under placebo 
conditions (26.9±5.9), t(15)=3.6, p=0.003 (Figure 1.7b). Performance in the n-Back 









Figure 1.4 Performance in the The 
Rey Auditory Verbal Learning Task 
(RAVLT) following intravenous 
THC (2.5mg) or matched placebo. 
Mean±s.e scores are shown for 
consecutive trials of working 
memory (A1-A5) and for free recall 











THE EFFECT OF THC ON VERBAL MEMORY
TRIAL































































Figure 1.5 Performance on the digit-span task 
following intravenous  THC  (2.5mg) or placebo. 















Figure 1.6 Performance on the verbal fluency task 














Figure 1.7a Performance on the N-back task 
following intravenous THC (2.5mg) or placebo. 
Mean±s.e are shown at increasing levels of 

































































THE EFFECT OF THC ON



























 THC PLASMA CONCENTRATION
Time (mins.)

































Following IV THC (2.5mg over 5 minutes), plasma concentrations reached a 
maximum and then decreased rapidly over 15 minutes. Thereafter, concentrations 
decreased at a slower rate (Figure 1.8). At 1 minute post-injection the plasma 
concentration of THC ranged between 96.1 and 206.6 ng/mL (mean±SD: 
176.7±33.7). Peak plasma concentrations of the main psychoactive metabolite of THC 
- 11-OH-THC - occurred at 5-minutes post-injection and ranged from 1.5 to 7.8 
ng/mL (mean±SD: 4.4±2.1). THC area under the curve from time 0 to infinity (AUC0-























administration of THC 
(2.5mg). Error bars 
show ± 95% CI. 
Figure 1.7b Performance on the 
Baddeley Reasoning  task following 
intravenous THC (2.5mg) or 
placebo. Mean±s.e are shown. 





The observed plasma concentrations and time-course of THC in the present study are 
in a similar range to those from previous studies in which individuals smoked 
cannabis cigarettes. In a study of healthy males, mean plasma levels of THC 
immediately after 10 puffs from cannabis cigarettes containing 1.75% or 3.55% THC, 
were respectively 56.2 and 146.6 ng/mL151. Ramaekers and colleagues investigated 
the properties of high-potency marijuana cigarettes containing 13% THC in a sample 
of recreational cannabis users. The mean (SD) serum THC concentration at 5 minutes 
post-smoking was 93.6 (63.9) ng/mL152. In the present study, the mean (SD) plasma 
THC concentration at 5 minutes post injection was 68.0 (14.1) ng/mL.  
 
Psychological responses to THC began during the redistribution phase (~5-10 minutes 
post injection) when the plasma concentration of THC had already fallen sharply 
(Figure 1.8). The majority of the psychological effects tapered off between 60 and 
120 minutes post THC, despite the relatively small change in the absolute plasma 
concentration during that period (Figure 1.8). Thus in agreement with previous reports 
the onset, peak and termination of psychological responses to THC were not related to 
concurrent plasma concentrations153.  
 
Positive Psychotic Symptoms  
There was wide inter-individual variation in psychosis scores. At 30 minutes post-
injection, 50% of subjects had increases in the PANSS positive subscale score ≥ 4, 
and similarly, 47% of subjects endorsed positive subscale items from the CAPE-state. 
Under THC conditions there was a significant correlation between increases in 
PANSS-positive and CAPE-state positive scores at 30 and 80 minutes. This suggests 
that phenomena which were categorised as psychotic were likely to be ‘true’ 
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psychotic experiences. THC-psychosis as measured by the PANSS or the CAPE-state 
did not correlate with THC elicited anxiety suggesting that THC-elicited acute anxiety 
and THC-elicited acute psychosis are separable psychological effects. The most 
commonly endorsed items on the CAPE-state under THC conditions at 30 minutes 
post injection were Q.2 Do you feel as if people seem to be dropping hints about you 
or saying things with a double meaning?, and Q.30 Do you hear your own thoughts 
being echoed back to you?  
 
Negative symptoms  
IV THC elicited self-reports of schizophrenia-like negative symptoms as rated by the 
CAPE scale. The most commonly endorsed items at 30-minutes post-injection were, 
1) Do you feel that you are not much of a talker at the moment? 2) Do you feel that 
you are not very animated? 3) Do you feel that you are lacking in energy / motivation 
/ spontaneity? 4) Do you feel that you experience few or no emotions at this time? 
Self-reported negative symptoms were unrelated to sedation. Scores on the 
investigator-rated PANSS negative subscale were also increased under THC-
conditions. However the effect size was numerically small and showed no correlation 
with CAPE-rated self-reports of negative symptoms. Whereas the presence of positive 
symptoms appears to be ‘obvious’ to participant and investigator alike, instruments 
such as the PANSS may be unsuited for quantifying experiences of negative 
symptoms in acute pharmacological studies. 
 
Affect 
 As hypothesized, THC elicited pronounced (largely unpleasant) changes in core 
affect. Overall, participants were more likely to rate themselves on the UMACL as 
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dysphoric and anxious in the first hour following THC. (Anecdotally, many subjects 
gave verbal reports of feeling more relaxed following THC but in the majority of 
cases their verbal reports were in contradiction to their self-rated scores on the tense-
arousal dimension of the UMACL and the overall clinical impression. Perhaps this 
reflects an underlying, widely-held assumption that cannabis has tranquilising 
properties.) Dysphoria and anxiety appeared to peak in the early stages following IV-
THC and subsided quicker than subjective feelings of tiredness, which peaked later 
and were more persistent. 
 
Animal and human work suggests that the effects of THC on anxiety is biphasic, with 
lower doses being anxiolytic and higher doses being anxiogenic61. The anxiety 
response observed here and in the study by D’Souza et al 2004 may be attributable to 
high plasma levels of THC. Clearly, the setting and drug-delivery method are far 
removed from the naturalistic way of taking cannabis and may have facilitated an 
anxiety response. 
 
Cognitive Function: In the 30 minutes following THC administration, there were 
marked deficits in working memory and executive functioning and a trend towards 
impaired episodic memory, all of which are largely consistent with previous studies64, 
154. In the sample here we found no suggestion of any relationship between the extent 
of positive psychotic symptoms and working memory/executive function. The extent 
of positive psychotic symptoms was related to impairments in episodic [hippocampal-





In a sample of healthy male subjects, a pure, synthetic IV preparation of THC elicited 
acute positive psychotic symptoms, negative symptoms, anxiety, dysphoria, working 
memory/executive deficits and subsequently, feelings of tiredness. Positive psychotic 















































Animal work has demonstrated that THC stimulates burst-firing of midbrain 
dopamine (DA) neurons and increases DA release at terminal fields in the striatum132, 
134, 155. Given that excessive striatal dopamine has frequently been implicated in 






1. Compared with placebo, THC would elicit a decrease in specific [123I]-IBZM 
binding in the striatum (an index of DA release).  
 
2. The magnitude of [123I]-IBZM displacement would show a relationship with 






















The study was carried out in the Institute of Nuclear Medicine, University College 
Hospital (UCLH), University College London, following approval from the South 
London and Maudsley Regional Ethics Committee and from the United Kingdom 





The psychological properties of IV THC (2.5mg) were investigated in an 
experimental study utilising a within-subject, double-blind, placebo-controlled design. 
Participants attended 2 experimental sessions, at least 2 weeks apart, in which either 




Healthy male participants between 21 and 50 years who fulfilled  





Dronabinol (THC) 2.5mg IV over 5-minutes, as in study 1.  
 
[123I]-IBZM at 185MBq was obtained from commercial sources (GE Healthcare, 
Eindhoven). Participants were given potassium iodate tablets for thyroid protection as 










Previous work has shown that following a bolus injection, specific [123I]-IBZM 
binding reaches a plateau by 45-60 minutes157.  Verhoeff et al. (1991) advised that 
optimal scan time was between 60 and 150 minutes158.  Here, participants received a 
bolus dose of [123I]-IBZM (185MBq) two hours prior to the onset of a 120 minute 
duration SPET scan. Forty-five minutes into the scan, participants were administered 
either IV THC (2.5mg) or placebo in a randomised, counterbalanced order. In both 
sessions, the first 0-45 minutes was used as a baseline. This permitted 30 minutes for 
the establishment of a new [123I]-IBZM pseudo-eqilibrium. Scanning data collected 
between 75-120 minutes were the defined drug/placebo blocks.  
 
SPET Data Acquisition 
 
SPET data was acquired using a triple detector Prism 3000XP (Philips Medical 
Systems, Cleveland, Ohio) camera with an ultra-high resolution low-energy fan-beam 
collimators. The images were acquired in a 128x128 pixel matrix. The images were 
reconstructed and checked for motion artefacts. Acquisition of each SPET image took 
approximately 120 minutes. 
 
 
SPET Data Processing and Analysis 
 
Images were reconstructed into five minute time periods. These were condensed into 
fifteen minute sequential time slots to improve the signal-to-noise. Reconstructed 
image data were assessed using Hermes software (Hermes Medical Solutions, 
Stockholm), a validated semi-automatic method of assessing tracer uptake in the basal 
ganglia159. Hermes was used to extract counts data for the left and right caudate, and 
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left and right putamen. The occipital cortex was used as a reference region since it 




Psychological assessments were administered at baseline (30 minutes prior to 
injection) and at 30, 80 and 120 minutes following the final injected (THC) pulse.  
 
 
1. Psychotic Symptoms 
 
Instrument: The PANSS, as in study 1. 
 
 
2. SPET data 
 
Counts in the caudate and putamen were compared to background (occipital cortex). 
The counts calculation used was (Area of Interest – Background) / Background. The 
subtraction index was then calculated: ((Area of Interest – Background) / 
Background)*100, as this addresses individual and scan differences160. The 






Blood (5mL) was collected at baseline and at 1, 5, 15, 30, 60 and 120 minutes post-
injection, and stored at -70ºC until analysis for [THC] and its major metabolites. 





Differences in PANSS scores under THC v placebo conditions were analysed using 
Friedman’s test. Differences in the D2-binding index were analysed using a repeated 
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measures ANOVA. Factors were Treatment (THC v placebo), Region (left caudate, 
right caudate, left putamen, right putamen) and Time (0-45min bin, 75-120min bin). 
In addition, differences in the D2-Binding index [i.e. from ‘baseline’ (0-45min bin) 
minus post-treatment (75-120 min bin)] in the two treatment arms (THC v placebo) 
were compared using a paired t-test. Correlations between positive psychotic 
symptoms and changes in the D2-binding index were analysed using Spearman’s rho. 








Of 11 recruited subjects, 10 completed both arms. Scanning failure in 1 session (a 
placebo arm) meant complete SPET data across both sessions was available for 9 
subjects. Plasma concentrations over time following the administration of THC are 







Figure 2.1 Mean plasma 
concentrations following the 
intravenous administration of THC 
































THC induced positive psychotic symptoms 
 
Scores on the PANSS positive subscale were increased from baseline following THC 























The D2 Binding Index (‘Dopamine release’) 
 
There was a strong trend for increases in the D2 binding index in the 75-120min bin 
compared to the 0-45min bin (F=3.85, p=0.09), but no effect of treatment (F=1.3, 
p=0.3) and no interactions. In Figure 2.3, there is an impression of ‘slower’ IBZM 
accumulation in the caudate nuclei in the THC compared to the placebo treatment 
arm, but numerical differences were not significant; [even if the right and left caudate 




There was no relationship between PANSS positive symptom scores and change in 
the D2 binding index following THC treatment (rho=0.15, p=0.7) 
INVESTIGATOR RATED POSITIVE PSYCHOTIC 
SYMPTOMS DURING SPET RECORDING
TIME (mins)




















Figure 2.2 Following the 
administration of IV THC 
2.5mg, healthy participants 
experienced positive 
psychotic symptoms 
(mean±s.e), as rated by The 
positive & negative 













Fig 2.3 The D2 binding index (region of interest-background/background *100) in 4 
basal ganglia regions (right & left, caudate nucleus & putamen), under THC versus 
placebo conditions. THC (2.5mg)/placebo were injected over 5-minutes, beginning at 








THC-psychosis and IBZM displacement (Dopamine release) 
 
The main finding in this study is that IV-THC, at doses sufficient to elicit psychosis, 
shows no significant difference from placebo in stimulating dopamine release in the 





























































































striatum. This suggests that the psychotomimetic properties of THC are not mediated 
by activation of the mesostriatal dopamine system. Furthermore, in this [admittedly 
small] sample, positive psychotic symptoms and striatal dopamine release were not 
related. The most prominent THC-elicited psychopathology occurred in the domains 
of delusional ideation and suspiciousness. Other subjective experiences reported 
included thought echo (n=1), auditory hallucinations (n=2) and passivity phenomena 
(n=2).  
 
Two recently published studies have used neurochemical imaging to measure 
dopamine release in man following THC. Utilising PET, Bossong and colleagues 
(2009) showed that specific [11C]raclopride binding was decreased (by ~3.5%) in the 
ventral striatum and precommissural dorsal putamen after inhalation of THC, 
although THC-psychosis was not observed in any of the subjects (n=7).  In a larger 
PET study (n=13), Stokes and co-workers (2009) found no significant difference in 
striatal [11C] raclopride binding between oral THC and placebo sessions (although 
binding in the frontal and lateral temporal cortices was decreased under THC 
conditions116). In the Stokes et al study, participants reported perceptual illusions and 
rapidity of thinking. Overall, the three studies suggest that, relative to other 
substances; nicotine, cocaine and amphetamines (Laruelle et al., 2000) THC does not 
evoke large increments in striatal dopamine release as measured by neurochemical 
imaging in humans.  
 
THC-psychosis and dopamine  
 
The above interpretation is in keeping with two previous pharmacological studies. In 
stable, schizophrenic patients, the administration of IV THC (2.5mg and 5 mg) led to 
marked increases in PANSS-positive scores, despite ongoing D2-receptor based anti-
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psychotic treatment99. Similarly, in healthy controls, pre-treatment with haloperidol 
had no effect on acute THC-psychosis161, although see Liem Moolenaar et al 2010162. 
At present, there is very little evidence to support the hypothesis that THC-psychosis 




The major limitation in the study here is that numbers are small, although similar in 
size to previous SPET/PET displacement studies assaying dopamine release following 
nicotine163, amphetamines164 or THC165, 166. Also SPET has poorer spatial resolution 
compared to PET. A strength is the use of IV-THC, which evokes a robust psychotic 
response, characterised by delusions of reference and suspiciousness. Future studies 







The basis for suspecting that dopamine mediates the pro-psychotic properties of THC 
















Animal work has shown begun to unravel the effects of THC on network dynamics. 
Robbe and colleagues showed that THC decreased the power of theta, gamma and 
ripple oscillations in the hippocampus, effects which could be blocked by CB1 
antagonists58. In agreement, Hajos and co-workers found that CB1 agonists disrupted 
theta and gamma oscillations within the septo-hippocampal system, and disrupted the 
P50 auditory-gating response, one of the most robust intermediate phenotypes in 
schizophrenia129. 
 
In humans there have been several recent reports of the effects of cannabis on 
neuronal oscillations, recorded using electroencephalography (EEG). Gevins and 
colleagues analysed EEG power in 10 subjects, during the performance of cognitive 
tasks.   Working and episodic memory performance was poorer following inhaled 
marijuana (3.5% THC). The principal EEG findings were decreased global theta 
power and reduced alpha band reactivity167. Similarly in a study of inhaled marijuana 
(0, 29, 49 & 69mg) in 16 participants, Bocker and co-workers observed a dose-
dependent decrease of resting theta and beta power. Furthermore, decreases in theta 





The starting point in the present study was to confirm the effect of THC on theta 
power. Thereafter the aim was to characterise the effects of THC on EEG coherence 
during WM performance. Coherence is a measure of the correlation between a pair of 
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signals as a function of frequency. It is regarded as an index of the functional 






The most robust EEG changes under THC would be associated with THC-elicited 









A randomised, double-blind placebo controlled crossover study in healthy volunteers 
of the effects of IV THC (1.25mg) on working-memory performance, 
psychopathology and concurrent EEG activity.  [The lower dose was used to 




Twenty healthy participants were recruited according to the criteria described in study 
1, except that female participants were also recruited.  (Female participants were also 
tested for possible pregnancy using a standard HCG urine screen). Sessions were 
performed at least two weeks apart and started between 0900 and 1400 h.  Placebo 
and THC were administered under double-blind conditions, in a randomised 











Psychological assessments and self-rated scales were administered at baseline (30 
minutes prior to injection) and at 30, 90 minutes post pharmaceutical.  
 
1. Psychotic Symptoms 
 
Instruments: The PANSS (see study 1). 
 
 
2. Cognitive Testing 
 
Immediately following the psychiatric assessment at 30-mins post-pharmaceutical, 
participants were administered a standard computerised version of the n-back task149.  
The n-back procedure has been used extensively to measure human working memory 
performance149. Participants were required to monitor a series of letters and report 
when the current letter matched the letter n integers back, where n=1 (1-back) or n=2 
(2-back), the latter being more difficult. The task requires continuous updating of 
information stores. In contrast, in the 0-back condition (which does not require 
manipulation of material in WM), participants responded to the appearance of a pre-
specified letter. Overall, the task consisted of alternating 30-second blocks of 0-back, 
1-back and 2-back conditions, and lasted 6 minutes in total. Within blocks, letters 
were displayed every 2 seconds for 1 second. Written instructions were read out and 
participants were given a practice run to demonstrate their understanding of the rules. 
Subjects were seated ~66cm from a CRT monitor and instructed to report correct 
answers as rapidly as possible by pressing a joy-pad button with their R-index finger. 







Blood samples were taken at baseline and at 1, 5, 15, 60, and 120 min after dosing, for 




All data recording and signal processing were performed in Neuroscan 4.3. EEG 
activity was recorded from 63 electrode sites using a Quik-Cap system 
(Compumedics), with a linked mastoid reference and ground at AFz. All impedances 
were maintained below 10 kO. Additional electrodes were placed at the outer canthi 
to measure horizontal electrooculographic (EOG) activity (monopolar with linked 
mastoid reference). Vertical EOG was measured using a bipolar recording with 
electrodes above and below the left eye. The EEG was sampled at 2000 Hz and 
corrected for eyeblinks using a regression approach. The corrected EEG was epoched, 
using a 10% Hanning window, into 2048 ms segments (-24 to 2024 ms with respect to 
each n-back letter stimulus). Epochs were baseline corrected. For each of the three n-
back conditions, average power within the frequency bands delta (1–3.5Hz), theta 
(3.5–7 Hz), alpha (8–13 Hz), beta (14–25Hz), low-gamma (30–40 Hz), and high-




For the power analysis, individual electrodes were grouped as left frontal, LF (F1, F3, 
F5, F7, AF3); right frontal, RF (F2, F4, F6, F8, AF4); left central, LC (C1, C3, FC1, 
FC3); right central, RC (C2, C4, FC2, FC4); left temporal, LT (FT7, T7, TP7, CP5, 
P7); right temporal, RT (FT8, T8, TP8, CP6, P8); left occipito-parietal, LOP (O1, 
PO5, PO3, P3, P1); and right occipito-parietal, ROP (O2, PO6, PO4, P4, P2). The 
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mean value from each group of electrodes was used for statistical analysis. The 





For the coherence analysis, the data were transformed to bipolar derivations. These 
derivations consist of pairs of neighboring electrodes at different scalp locations to 
eliminate the contribution of activity from a common reference to the coherence 
estimate. Bipolar channels were derived for left and right frontal and parietal regions 
(F3/F5; PO3/PO5; F4/F6; PO4/PO6). The measure of coherence used is equivalent to 
a Pearson’s correlation performed with complex numbers. It measures the correlation 
(a value between 0 and 1) of EEG activity in a specific frequency band between two 
scalp locations. For each of the three n-back conditions, coherence measures were 
calculated between three prespecified inter-regions, left frontal–left parietal F3/F5-






Distributions were checked for normality using Kolmogorov-Smirnov statistics. Non-
parametric tests were used to analyse PANSS data, because of floor effects under 
placebo conditions; Thus differences between THC v placebo sessions were assessed 
using Friedman’s test and relationships between PANSS scores and EEG measures 
were analysed using Spearman’s rho. Accuracy and speed of performance in the n-
back were analysed by repeated measures ANOVA, with task-difficulty and THC-
treatment as within-subjects factors. Relationships between n-back data and EEG 
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measures were analysed by Pearson’s correlation coefficient. Repeated measures 
ANOVA was used to analyse EEG power, with recording site, task-difficulty and 
THC-treatment as within-subjects factors. Individual ANOVAs were conducted for 
each frequency band delta to gamma. EEG coherence was analysed by repeated 
measures ANOVA with THC-treatment, region, task-difficulty and frequency as 
within-subjects factors. All ANOVAs were Bonferroni-corrected. Where sphericity 
assumptions were violated, Huynh-Feldt corrected statistics were used. Post-hoc t-
tests were carried out where appropriate. Correlations between psychological 
outcomes and EEG measures were Bonferroni corrected to adjust for multiple 














Overall, 16 of 20 participants (7 male, 9 female) completed both sessions of the study.  
Two participants were lost to follow up.  One subject discontinued her involvement 
and one subject experienced short-lived panic and the session was stopped 
prematurely.  Mean age was 26 ± 6 years.  Prior to experimental sessions, all urine 
drug screens were negative.  Previous use of cannabis ranged from 2 to approximately 
1000 occasions (median = 40).  With regard to other drugs, 11 (of 16) had previously 
taken stimulants (cocaine/amphetamines), 6 had taken MDMA, 6 had taken 
psychedelics (psilocybin/LSD) and there was a single case each of previous ketamine 
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and GHB. Plasma concentrations of THC over the course over the experiment are 







Figure 3.1 Mean plasma 
concentrations following the 
intravenous administration of THC 






















Compared to placebo, THC increased positive (Friedman’s χ2=63.7, p<0.001) 
negative (Friedman’s χ2=56.0, p<0.001) and general PANSS scores (Friedman’s 
χ2=36.1, p<0.001). Increases were most pronounced at the 30-minute assessment 
point and tended back towards baseline by 90-minutes (Figure 2a, b). Overall, 40% of 
participants showed increases in PANSS positive symptom scores of >4 points at 30-
minutes post-injection (Figure 3.2). 
THC PLASMA CONCENTRATION
TIME (mins)























Figure 3.2 Following the 
administration of IV THC 1.25mg, 
healthy participants experienced 
positive psychotic symptoms 
(mean±s.e), as rated by the positive 











There was a trend towards reduced accuracy in the n-back task following treatment 
with THC (F=2.95, p=0.11). Accuracy was robustly affected by task-difficulty 
(F=5.38, p<0.005), with poorer performance in the 2-back condition compared to both 
the 1-back (p<0.05) and 0-back (p<0.01) conditions (Figure 3.3). In terms of 
accuracy, there was no THC-treatment x task-difficulty interaction. 
Response times in the n-back task were slower under THC versus placebo conditions 
(F=6.8, p<0.05), and as task-difficulty increased (F=32.3, p<0.001). There was an 
interaction between THC-treatment x task-difficulty, in that the effect of THC was 



































The effect of THC on response accuracy



















The effect of THC on response times



































































Figure 3.3 Under THC 
conditions, there was a 
trend for less accuracy in 
the most difficult condition 
of the N-Back task, but 








THC decreased theta power (F=23.5, p<0.001),  
 
of task difficulty or recording site (Figure 3.4 a, b, c). There was also a trend towards 
decreased alpha power under THC (F=3.74, p=0.07), with no treatment x task 
difficulty or treatment x recording site interactions. Power in the beta, delta and 


















EEG Power following THC
FREQUENCY























(electrode Fz) was 
reduced under 
THC conditions. 
There was a strong 
trend for a 
decrease in alpha 
power under THC, 
whereas delta, beta 
and gamma bands 
were unaffected.
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THETA power under THC v placebo according to region
REGION









































Figure 3.4c Under THC 
conditions, theta power 
was reduced across 
recording sites. (Left 
frontal, LF; Right Frontal, 
RF; Left central, LC; 
Right central, RC; Left 
temporal, LT; Right 
temporal, RT; Left 
occipitoparietal, LOP; 
Right occipitoparietal, 
ROP; Midline frontal, FZ; 
Midline parietal, PZ; 
Midline central, CZ. 
 
Figure 3.4b Under 
THC conditions, 
midline frontal 
theta power was 
reduced at all 
levels of task 





There were overall effects of region (F=9.8, p<0.01), frequency (F=16.6, p<0.001), 
task-difficulty (F=24.3, p<0.001), and THC (F=6.1, p<0.05). EEG coherence was 
greater between bi-frontal electrodes, compared to L-fronto-parietal (p<0.05) and R-
fronto-parietal (p<0.05) electrode pairs. Compared to the 0-back condition, overall 
coherence increased under the 1-back (p<0.001) and 2-back conditions (p<0.005).  
 
Interactive effects were region x frequency (F=4.0, p=0.01) and frequency x THC 
(F=3.1, p<0.05). There was a trend towards a 3-way interaction between region, 
frequency and THC-treatment (F=2.0, p=0.09). 
 
Under placebo, bi-frontal coherence was largest in the theta band and theta coherence 
was greater between bi-frontal region compared to both the left (p=0.01) and right 
(p<0.005) fronto-parietal regions. THC selectively decreased coherence in the theta 




EEG Power and psychopathology 
 
Overall there was no correlation between change-in theta power, either globally or 
specifically at electrode Fz, and (1) reaction-time in the n-back task, (2) positive 
PANSS scores or (3) negative PANSS scores.  
 
EEG coherence and psychopathology 
 
I investigated possible relationships between reductions in theta and alpha coherence 
and three psychological outcomes, positive symptoms, negative symptoms and 
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reaction time in the n-back task. Since there were six comparisons in total, statistical 


























The change in theta coherence (averaged over bi-frontal, and left and right fronto-
parietal) under THC conditions was strongly associated with positive PANSS scores 
(rho=0.75, p=0.001), but neither negative symptoms nor reaction-time in the n-back. 
The relationship between theta coherence and positive symptoms was specific for the 
                  
 
 
Figure 3.5 Coherence between left and right prefrontal regions, 
under THC v placebo, in the control (0-back) and most 
challenging (2-back) levels of the n-back task. Bars show 
coherence (mean±SEM) by frequency. (Diagonal stripes, delta; 
black, theta; grey, alpha; white, beta.) THC selectively 
decreased coherence in the theta (p<0.05) and alpha (p<0.05) 
bands. 

















bi-frontal region (rho=0.79, p<0.001). Change in left fronto-parietal or right fronto-
parietal theta coherence was unrelated to positive symptoms. Reduced bi-frontal theta 
coherence occurred at all levels of the n-back, and survived the removal of 2 potential 
outliers (rho=0.69, p=0.006) (Figure 3.6). 
 
There was a weaker relationship between the change-in alpha coherence and negative 
symptoms (Averaged rho=0.57, p=0.02) which was insufficiently robust to survive 
correction for multiple testing, and no relationship with positive symptoms nor 







The Relationship between positive psychotic symptoms 
& bi-frontal theta coherence
Change in theta coherence (Placebo-THC sessions)



























Figure 3.6 Reductions in theta coherence between left and right 
prefrontal regions under THC was correlated with positive psychotic 
symptoms (rho=0.79, p<0.001), and survived the removal of two 







The major finding from the present study was that THC decreased theta coherence 
between bi-frontal brain regions and that reductions from baseline were strongly 
associated with positive psychotic symptoms. Additional effects of THC in the current 
sample – transient psychosis, slower working-memory performance and global 
suppression of power in the theta band- are consistent with previous reports.  
 
Previously there has been speculation that the pro-psychotic effects of THC stem from 
disruption of synchronised neural rhythms129, 130. The findings here provide 







Global theta power was reduced by THC – without any manifest psychopathological 
consequences. In contrast, there was a strong and specific association between THC-
induced positive psychotic symptoms and reduced bi-frontal theta coherence.  
Impaired functional 'cross-talk' between the frontal lobes in the theta band might 



















The pro-psychotic properties of cannabis are attributable to THC. Another plant-
derived molecule, cannabidiol (CBD) is reported to display anti-psychotic properties 
in animal models and in humans169-172. Animal work and early human studies 
suggested that CBD could antagonise some of the pharmacological effects of THC115, 
173.  
 
In the UK, new forms of cannabis (sinsemilla), which contain high concentrations of 
THC but negligible concentrations of CBD, now dominate the illicit cannabis market 
and there is concern that sinsemilla might be more hazardous for mental health than 
traditional cannabis84. Some have speculated that it is the absence of CBD, rather than 
rising concentrations of THC, which is important82. Here we tested whether CBD 
could inhibit the pro-psychotic effects of THC. [The receptor pharmacology of CBD 





It was hypothesized that THC-elicited positive psychotic symptoms, would be 


















A within-subjects, placebo-controlled, double-blind investigation of whether 




Six healthy participants were recruited according to the criteria described in study 3. 
Participants attended for 2 experimental sessions at least 2 weeks apart. Placebo and 
CBD were administered under double-blind conditions, in a randomised 
counterbalanced order, immediately prior to THC. All injections were administered 




Dronabinol (THC) 1.25mg IV  





Positive psychotic symptoms were assessed at baseline and at 30 minutes and 90-















At 30 minutes post-dosing, THC-elicited PANSS positive symptoms were lower 




























The finding that ‘a mixture’ of CBD and THC is less psychotogenic than an 
equivalent dose of THC on its own suggests that CBD ‘protects’ against THC-induced 
psychosis. The results support the view that the psychotogenicity of sinsemilla may 





Small sample size. 
 CBD or Placebo versus THC
TIME (mins)





















Figure 4.1 THC-elicited 
positive psychotic 
symptoms were decreased 











In study 4 it was found that that pre-treatment with IV CBD (5mg) inhibited IV THC 
(1.25mg) evoked positive psychotic symptoms, as measured by the Positive & 
Negative Syndrome Scale (PANSS), although the small sample size (crossover, n=6) 
limited definitive conclusions. Since then, a series of community studies have 
addressed this issue. 
 
1. In a highly original design, Morgan and Curran measured trace cannabinoid levels 
in hair samples from regular cannabis users as well as scores of psychosis proneness 
as rated by the OLIFE (Oxford Liverpool Inventory of Life Experiences) instrument. 
Regular users who were grouped as THC-positive/CBD-negative scored higher than 
regular users who were positive for both cannabinoids on scores of unusual 
experiences174.  
2. In an epidemiological study in South London, Di Forti and colleagues compared 
patterns of drug use in people presenting with a first episode of psychosis with healthy 
controls. Patients and controls were equally likely to have ever taken cannabis and 
started at the same age. Although patients were more likely to be daily-users the most 
striking difference was that they were approximately 7-times more likely than 
controls to be users of sinsemilla175. 
3. In Holland, the most popular types of cannabis sold on the market are measured 
annually for THC and CBD content. Schubart and colleagues combined this 
information with data on cannabis use from approximately 1900 people, and found 
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that the THC/CBD ratio was related to subclinical psychotic experiences as rated by 
the CAPE-scale (Community Assessment of Psychic Experiences). Subjects who used 
products with a high THC/CBD ratio reported significantly higher CAPE-total scores 
than those using products with a low THC/CBD ratio. In heavy users, (spending 
upwards of 50-Euros/week on cannabis), higher CBD content was associated with 





Here I conducted a larger study (between groups, n=48) in which IV THC (1.5mg) 
followed pre-treatment with either oral CBD (600mg) or placebo. I hypothesized that, 
following IV THC, the group who had been pre-treated with CBD would show less 
positive symptoms and less cognitive impairment than the group that had been pre-






A 2x3 mixed design. Participants were randomly allocated in a counterbalanced 
fashion to placebo or CBD groups. Placebo/CBD capsules were administered under 
double-blind conditions. Each participant was assessed in three separate sessions: 1. 








Capsules (placebo/CBD) were administered 3h-30 minutes prior to IV THC 
challenge. 
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Pre-treatment; Cannabidiol (2 x 300mg capsules) or matching placebo. Oral capsules 
of CBD (300mg) and matching placebo were obtained from STI Pharmaceuticals UK.  
THC 1.25mg IV over 10 minutes. 
 
Baseline Predictive Instruments 
 
Prior to the experimental session, participants completed the following questionnaires 
online: The Green et al paranoid thoughts scale (GPTS) Part B, which provides a 
measure of trait paranoia177, The Cannabis experiences questionnaire, which 
quantifies psychotic/dysphoric experiences following recreational cannabis use178, and 
the Schizotypal personality questionnaire179. This permitted assessment of whether 




Positive Psychotic Symptoms 
 
The positive dimension was assessed using two instruments:  
1. The PANSS, as in study 1. 
2. The State-social-paranoia-scale (SSPS)  
The State Social Paranoia Scale (SSPS)180 
The SSPS has ten persecutory items (e.g. “Someone wanted me to feel threatened”), 
each rated on a 5-point scale, which conform to a recent definition of persecutory 
ideation. The SSPS has excellent internal reliability, adequate test-retest reliability, 
convergent validity with both independent interviewer ratings and self-report 





1. The Hopkins verbal learning Task-Revised (Verbal learning & memory) 
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The Hopkins Verbal Learning Task (HVLT-R) 
In the HVLT-R, participants are tested in their immediate recall of 12 words (nouns 
from three taxonomic categories) after each of 3 learning trials. Here, delayed recall 
was assessed twenty minutes after the final learning trial. Three versions of the task 





Data were assessed for normality using Kolmogorov-Smirvov test statistics. In line 
with expectations, data on the PANSS and State-social-paranoia-scale were highly 
skewed necessitating the use of non-parametric approaches. Thus Friedmans test, a 
non-parametric repeated-measures test was used to analyse positive symptom scores 
on the PANSS and the State-social paranoia scale. In addition, for the PANSS we 
followed the approach of D’Souza and colleagues which is to categorize clinically 
significant psychosis as increases from baseline of >=3 points99. Thereafter the 
difference in the frequency of clinically significant THC-evoked psychotic reactions 
between the CBD and placebo groups was analysed using Pearson’s Chi-square. 
Normally distributed data were analysed by a general linear model (GLM), 
specifically repeated-measures ANOVA. The Within-groups factor was SESSION (1. 
Baseline 2. Post-capsule 3. Post-THC). The between-groups factor was pre-treatment 
GROUP (1. CBD 2. Placebo). Post-hoc analyses were performed with Bonferroni 
correction. Relationships between psychosis scores and cognitive data were analysed 
using Spearman’s rank correlation coefficient. Significance was accepted at p values 






Forty-eight subjects completed the experimental protocol (Placebo-group n=26; CBD-
group n=22). In three subjects, failure of cannulation prevented the administration of 
THC, and data acquired up to that point was not used in any of the analyses. The two 
groups were adequately matched for demographic variables, baseline measures of 
‘psychosis-proneness’ and previous drug use (Table 5.1).  
 
 
Table 5.1 Sample characteristics at baseline. The 2 groups (CBD & PLACEBO) were 
adequately matched for demographic variables, ‘psychosis-proneness’ as indexed by 
the SPQ, CEQ and Green et al Paranoia Scale, and for previous illicit drug use. BMI 





The plasma concentrations of CBD and THC over time are shown in Figure 5.1. 









Age (years) 26 (±4) 25 (±3) ns 
Sex ratio (m:f) 14:12 13:9 ns 
BMI 25 (±5) 25 (±4) ns 
SPQ (Total) 11.1 (±7.0)  12.1 (±11.2) ns 
CEQ (Paranoia/dysphoria) 43.0 (±9.1) 42.8 (±10.4) ns 
The Green Paranoia scale 19.3 (±5.0) 23.7 (±10.2) 0.08 
Previous cannabis use (Episodes) 118 (±218) 137 (±234) ns 
Age at first cannabis use 16 (±2) 17 (±2) ns 
 
      Previous Drug Use (Yes) 
‘Ecstasy’ 62.5% 48% ns 
Cocaine 54% 40% ns 
‘Acid’ 21% 20% ns 
Ketamine 21% 32% ns 
Amphetamines 13% 16% ns 
Mephedrone 17% 36% ns 
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to decrease. THC concentrations were not significantly different between the group 
pre-treated with CBD and the group pre-treated with placebo at 5-minutes (p=0.5), 
30-minutes (p=0.5) and 80-minutes (p=0.6) post-THC administration. Plasma 
concentrations (mean ng/ml±SEM) of the psychoactive metabolite 11-OH THC were 
higher in the CBD group compared to the placebo group at the 5-minute (2.13±0.43 v 
0.37±0.13, p=0.001), the 30-minute (1.18±0.32 v 0.00±0.00, p<0.005) and 80-minute 
(0.69±0.19 v 0.00±0.00, p<0.005). 
 
 
Concentrations of CBD & THC
over Time
TIME (mins)




















Figure 5.1 Plasma cannabinoid concentrations (mean ±SEM). Oral CBD (600mg) 
was administered at 0-minutes. THC (1.5mg) was administered by slow IV injection 
from 210-220 minutes. In the CBD pre-treated group and the placebo pre-treated 
group, differences in plasma THC concentrations at three successive sampling points, 
were not statistically significant. With respect to THC administration, plasma [THC] 













Compared to baseline conditions, THC administration increased PANSS positive 
scores, regardless of whether pre-treatment was with CBD (χ2=19.5, p<0.000) or 
placebo (χ2=26.0, p<0.000).  However clinically-significant positive symptoms 
following THC, defined as an increase in PANSS positive scores of >=3 points, were 
more common in the group pre-treated with placebo (11 of 26 cases) compared to the 




Pre-treatment with CBD inhibited THC-elicited paranoia as measured by the State-
social-paranoia-scale. Following the administration of THC, paranoia scores increased 
in the group pre-treated with placebo (χ2=16.0, p<0.000), whereas there was no 
change in paranoia scores from baseline in the group pre-treated with CBD (χ2=2.0, 
p=0.37) (Figure 5.2).  
 




Immediate recall was poorer following THC, regardless of group (CBD-group 
F=10.5, p<0.005; placebo-group F=12.6, p<0.000). Post-hoc analysis revealed 
differences between post-THC and baseline performance, significantly in the placebo-
group (p<0.005), and at the level of a strong trend in the CBD-group (p=0.06). 
Differences between post-THC and post-capsule performance were significant in the 























Pearson Chi-Square=4.74, p<0.05 


























Table 5.2 Pre-treatment with Cannabidiol, CBD (600mg po) reduced the odds of 
developing an acute psychotic reaction to delta-9-tetrahydrocannabinol, THC (1.5mg 








Figure 5.2 Pre-treatment with 
Cannabidiol, CBD (600mg po) 
inhibited delta-9-
tetrahydrocannabinol, THC 
(1.5mg IV) evoked paranoia, as 
measured by The State-social-





















Following THC, immediate recall was 2.9 (±5.3) and 3.6 (±4.5) items fewer in the 
CBD and placebo groups respectively, compared to baseline, a non-significant 




Delayed recall was poorer following THC in the placebo-group (F=7.7, p<0.01) but 
not in the CBD-group (F=1.5, p=0.2). Post-hoc analysis in the placebo-group revealed 
differences between post-THC and baseline (p<0.05) and between post-THC and 
post-capsule performance (p<0.05). Corresponding analyses in the CBD-group were 
p=1.0 and p=0.6 respectively. Following THC, delayed recall decreased from baseline 
by 10.7% (±18.9%) in the placebo group and by 0.4% (±9.7) in the CBD-group, a 





A-posteriori, we explored if there were relationships between impaired delayed recall 
and positive psychotic symptoms, post-THC. In the placebo group, poorer delayed 
recall was related to the magnitude of PANSS-positive symptoms, at the level of a 
strong trend (Spearman’s rho=0.3, p=0.09). The relationship between poorer delayed 
recall and higher scores on the state-social-paranoia scale was stronger and reached 













Immediate Recall following THC





































































Delayed Recall following THC





















Figure 5.3 (a) 
Immediate recall in the 
HVLT-R (mean ±SEM) 
was poorer following IV 
THC (1.5mg), in both 
the placebo and CBD 
(600mg po) pre-treated 
groups. (b) Delayed 
Recall was poorer 
following THC in the 
placebo but not the CBD 
pre-treated group. 







The major findings here are that pre-treatment with CBD decreased THC-elicited 
psychosis and inhibited the detrimental effects of THC on episodic memory.  
 
 
Cannabinoids and Psychosis 
 
The majority of community-based studies that have addressed the issue have proposed 
that cannabis products lacking CBD are more psychotogenic than products that 
contain CBD174-176, but see Morgan et al, 2010181. The findings in the present study 
provide strong support for this idea. Here, on the PANSS (an investigator-rated scale), 
clinically significant THC-psychosis was less likely under CBD versus placebo 
conditions. On the SSPS (a participant rated scale) THC-elicited paranoid thinking 
was inhibited under CBD conditions. 
 
Cannabinoids and Memory 
 
Cognitive performance was poorer following THC specifically in the domains of 
working and episodic-memory, which is in keeping with previous reports (reviewed in 
Ranganathan and D'Souza, 2006154; Solowij and Michie, 200764).  Here, pre-treatment 
with CBD ‘protected’ episodic-memory from the impact of THC, whereas working-
memory remained ‘vulnerable’ to a similar degree.  
 
This result is in broad agreement with a community-based study carried out in 
London by Morgan and Curran: Volunteers were assessed at home under the 
influence of their own chosen brand of cannabis, a sample of which was subsequently 
tested for THC and CBD content. It was found that higher levels of CBD in “street 





Systems Pharmacology  
How THC impacts upon episodic memory is reasonably well understood. Episodic 
memory depends upon the integrity of the hippocampal circuitry. Numerous animal 
studies have shown that CB1 agonists disrupt processes within the hippocampus that 
are believed to be at the heart of learning and memory - network oscillations, neuronal 
synchrony and plasticity182-185. Recently, CB1 agonists have become a useful tool in 
hippocampal research. This is because CB1 agonists disrupt synchronicity, without 
altering the firing rates of individual neurons in the network – a unique property 
amongst drugs which impact upon hippocampal function58. 
 
The mechanisms underlying the pro-psychotic properties of THC are less well 
understood. It has been suggested that disrupted network oscillations are important 129, 
130. The findings in study four provide experimental support.  
 
In the present data set, there was a relationship between THC-psychosis and THC-
elicited impairments in episodic memory. This was also observed in Study 1. 
 
Pharmacokinetics 
It is feasible that the differences between the CBD group and the placebo group 
emerged, not from a pharmacodynamic effect, but from an effect of CBD on the 
metabolism of THC. CBD is known to inhibit the metabolism of THC in rodents 
[increasing the plasma concentration of THC and decreasing the plasma concentration 
of the psychoactive metabolite 11-OH THC]186-189 although the effect is dependent on 
the time interval between administration of the 2 drugs190. To date, there is a paucity 
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of data on the pharmacokinetics of CBD/THC in humans. Here it was found that there 
was no difference between THC plasma concentrations in the CBD pre-treated versus 
the placebo group. At odds with the rodent studies described above, 11-OH THC 
concentrations were significantly higher in the CBD versus the placebo pre-treted 
group. The reason for this is unknown and clearly further studies in humans are 
required to address this issue.  
 
Strengths and Limitations 
 
In laboratory-based, pharmacological studies pure, synthetic preparations can be 
administered, at a set dose. This is particularly relevant for cannabinoid studies, 
because ‘street cannabis’ contains a multitude of other molecules, some of which are 
known to be pharmacologically active. One example is Δ9- Tetrahydrocannabivarin 
(THCV), a CB1 receptor antagonist at low doses, an agonist at higher doses81. A 
limitation in the present study is that only one dose of CBD was investigated. Future 
studies might examine if higher CBD doses, or indeed extended dosing over several 
days produces stronger ‘protective effects’ or if protection extends to additional 





Previous epidemiological and experimental studies have suggested that cannabis-
products lacking CBD are more psychotogenic than products containing CBD. The 
findings here provide strong support. Under controlled experimental conditions, CBD 
decreased THC-elicited positive psychotic symptoms and ‘protected’ hippocampal-









1. In a proportion of subjects, THC elicited positive psychotic symptoms, which 
appeared to be distinct from anxiety. 
THC also elicited negative symptoms, which appeared to be distinct form sedation. 
However the most common effect of THC is disruption in the sense of passage of 
time, attention and concentration (Appendix 1). 
 
2. In general THC impaired working memory, episodic memory and executive 
function. Impairments in episodic memory were related to positive psychotic 
symptoms in study 1, and this was replicated in study 5. 
 
3. There was little evidence for an effect of THC on striatal dopamine release, despite 
the induction of positive psychotic symptoms (including 1st rank symptoms). This is 
in agreement with two recent imaging studies. 
 
4. Under THC conditions, EEG power in the theta band was decreased. This is in 
keeping with animal work and two previous EEG studies. However decreased theta 
power did not show any relationships with the psychological manifestations of THC. 
Under THC conditions, theta coherence between the two frontal lobes was 
diminished. The decrease in bi-frontal theta coherence relative to baseline was 
strongly correlated with the magnitude of positive psychotic symptoms. 
 
5. Preliminary findings that CBD inhibits THC-elicited psychosis (Study 4) were 
confirmed in a larger study (Study 5). Additionally CBD inhibited the detrimental 
 95
effect of THC on episodic memory. The findings are in agreement with recent 
community-based studies that suggest that cannabis products lacking CBD are more 




































There are four main drug-models of endogenous psychosis: LSD, amphetamine, 
ketamine and THC. What is common between the different classes of drug is the 
promotion of a fundamental change in the subject’s experience of reality, whether 
acutely during drug intoxication or as a result of an adaptive process secondary to 
repeated use. Comparing the different drug-models, CB1 agonists can elicit a 
psychotic reaction in otherwise healthy controls after a single exposure, in contrast to 
stimulants (amphetamine/cocaine) where repeated use is a pre-requisite (A2.8). And 
repeated use of cannabis (especially forms high in THC-content) is a risk factor for 
the genesis of schizophrenia28, 175, in contrast to ketamine where no association has as 
yet been found. 
 
  
Is dopamine involved in THC psychosis? 
 
The glutamate and GABA inputs to the band of dopamine neurons in the ventral 
midbrain express CB1 receptors and numerous animal studies have shown that 
exogenous cannabinoids alter the balance of excitation and inhibition which ‘reach’ 
dopamine cells47, 155. Although a net inhibition of dopamine cells has been 
described191, by far the most commonly documented effect is an increase in firing and 
elevations of dopamine release in the striatum155 .  
 
Hence there are theoretical grounds for the hypothesis that the pro-psychotic effects of 
THC arise via dopamine. However the evidence to date has not been supportive. In 
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study 2 here, and in two additional neuroimaging studies165, 166, there was no evidence 
for substantial dopamine release in the striatum following THC. 
 
 
Abnormal Oscillations & THC psychosis 
 
Previously there has been speculation that the pro-psychotic effects of THC stem from 
disruption of synchronised neural rhythms129, 130. The major finding here provides 
experimental support. It may be considered that THC elicits a 'lesion', at the molecular 
level which can 'push' an otherwise healthy nervous system towards acute psychosis, 
hastens the onset of psychotic-breakdown in those destined to develop schizophrenia 
and provokes acute relapse in established cases192. The precise nature (and location) 
of the molecular lesion, downstream of CB1 receptors is unknown. But the most likely 
scenario is that THC disrupts the intricacies of fast amino-acid based 
neurotransmission; and in doing so, disrupts network oscillations which depend, in-
part, upon reciprocal glutamate and GABA-ergic connections58, 129, 193-195.  
 
The findings in study 3 point to the pre-frontal cortex and implicate the theta band. 
Reduced bi-frontal (but not fronto-parietal) coherence from baseline was strongly 
associated with positive psychotic symptoms. This was not the case for theta power. 
The simplest interpretation is that acute THC-psychosis is associated with disruption 
in long-distance synchrony but not with disruption of local theta rhythms. This 
interpretation is broadly in keeping with the disconnection hypothesis, in which 
impaired functional connectivity between brain regions underlies schizophrenic 
symptoms196  Some caution is required in attributing the pro-psychotic effects of THC 
to a direct action within the frontal cortices. It is likely that theta oscillations within 
limbic regions were also disrupted by THC58, 129. Thus an apparent cortical lesion 
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might only be a marker for a cortico-limbic lesion which is ‘closer’ to the 
pathophysiology of THC. For example Df(16)A+/– mice, (which mimic one of the 
largest genetic risk-factors for schizophrenia, a microdeletion on human chromosome 
22q11.2), show reduced phase-locking of pre-frontal cells to hippocampal theta 
rhythms and reduced coherence of pre-frontal and hippocampal local field 
potentials197.   
 
 
Abnormal oscillations & endogenous psychosis 
 
Abnormal neural oscillations occur in schizophrenic patients, and their relatives194, 195. 
The list of mental faculties affected by schizophrenia: perception, learning & 
memory, will, thinking; are also those which depend upon synchronised neuronal 
rhythms195. Initial work focussed on the gamma band, given the role of gamma-
synchrony in Gestalt perception; the binding of separate sensory elements into a 
perceptual whole198. Numerous studies have now shown abnormal gamma rhythms in 
schizophrenia, and a feasible histological correlate – neurochemical deficiencies in 
fast-spiking GABA-ergic interneurons125. But it has become clear that abnormalities 
are not confined to gamma rhythms194, 195. In the context of the findings reported here, 
studies in schizophrenic patients have reported decreased power of frontal theta 
oscillations during performance of WM tasks199, 200. Ford and colleagues compared 
the EEG of speech production versus listening, in patients and controls. Speech 
production was associated with increased coherence across classical left hemisphere 
language regions within the theta band, in healthy controls but not in schizophrenic 
patients201. The authors concluded that reduced fronto-temporal functional 
connectivity in schizophrenia could lead to the attribution of self-generated speech to 





Although theta oscillations have been implicated in the processes of working and 
episodic memory, their role is likely to be more general. Nowhere is this more 
apparent than in studies of septo-hippocampal theta in rodents, stretching back over 
sixty years. The list of putative behavioural correlates is extensive, and has been the 
source of some controversy, but “volition” or “will” is believed to play a critical role 
in theta generation137.  
 
At present the relationship between hippocampal theta and scalp recorded theta 
remains a matter of debate. Intra-cranial recording in humans (iEEG) indicate that 
there are ‘independent’ local cortical generators of theta202. In contrast, others have 
speculated that the cortex and hippocampal formation might operate as an integrated 
unit by means of synchronisation in the theta band203. In support of this idea, recent 
animal work has shown that neocortical spikes can be phase-locked to hippocampal 
theta oscillations204. Similarly, coupling of neocortical and hippocampal theta rhythms 
has been observed205.  
 
Despite the unresolved issues, there is a consensus that theta oscillations are important 
for long-distance ‘cross-talk’ between brain regions137, 195, 198. It is also appreciated 
that faster oscillations can 'nest' within slower oscillations; thus the power of gamma 








7.2 Cannabidiol: Potential Utility 
 
Studies 4 and 5 indicate that CBD can inhibit the pro-psychotic effects of THC. This 
is in keeping with findings from community-based studies174-176. Overall this has 
important public-health implications. The laboratory studies carried out here can be 
thought of as modelling acute cannabis exposure, whereas community studies 
represent repeated exposure. Both approaches point in the same direction: the absence 
of CBD is associated with increased THC-elicited psychosis and cognitive 
impairment.  
There is also interest in whether CBD represents a useful medicine for psychiatry.  In 
standard animal models, CBD has an anti-psychotic signature. Efficacy has been 
demonstrated in the apomorphine, amphetamine, ketamine, conditioned avoidance 
and pre-pulse-inhibition (PPI) models72, 77, 78, 207. CBD displays efficacy without 
eliciting motor side-effects (catalepsy)72. Preliminary findings suggest that CBD 
inhibits L-DOPA elicited psychosis in Parkinson's disease (Zuardi et al 2009 J 
Psychoparmacol 23). Also, in a 4-week RCT in acute schizophrenic patients (n=42), 
CBD had equal efficacy with amisulpride, and superior tolerability80. 
 
Receptor Pharmacology 
CBD targets a number of receptor, re-uptake and enzymatic. Deciphering the specific 
mechanism which lies at the root of a particular pharmacological property is 
challenging, particularly for CNS effects: At low concentrations CBD antagonises the 
GPR55 receptor208. There is evidence that GPR55 receptors are localised at 
glutamate terminals, where they function to amplify pre-synaptic glutamate release 
(Ross, personal communication). Blockade of GPR55, and inhibition of excessive 
glutamate release could feasibly underlie the anti-psychotic (and the anti-convulsant/ 
neuroprotective) properties of CBD. Similarly, at low concentration CBD antagonises 
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tissue responses to CB1 agonists (despite low affinity for the orthosteric site of the 
CB1 receptor)81. Antagonism of CB1 signalling is the most parsimonious explanation 
for the ability of CBD to inhibit THC elicited psychosis. At low concentration, CBD 
inhibits adenosine re-uptake, which may account for some of the observed 
behavioural effects. At higher concentrations, CBD is an agonist as the 5-HT1A 
receptor, a mechanism which has been proposed to underlie its acute anxiolytic 
properties [although 5-HT1A  mediated anxiolysis typically requires chronic dosing]. . 
Similarly at higher concentrations, CBD inhibits the cellular uptake and metabolism of 
anandamide. Some authorities have proposed the latter mechanism as important for 






The focus now is on whether CBD constitutes a useful medicine in psychiatric 
patients. Preliminary work suggests that CBD has utility in psychotic illness. In 
particular, CBD may be an attractive candidate for the at-risk-mental-state (the pro-




The effect of THC on bi-frontal theta coherence and the relationship with positive 
psychotic symptoms requires replication. Also, it is hypothesized that CBD inhibits 





The following questionnaire was devised on the basis of verbal reports from the 
participants in studies one and two (Table A1.1). The scale was used in subsequent 
experiments. Figures A1.1-A1.3 show endorsement of items at IV THC (1.25, 1.5 and 




          
ITEM No Minimal Moderate Strong Extreme 
1. Currently I'm interested in objects in the 
environment, more than usual           
2. My thinking is much faster than usual            
3. This experience is frightening.           
4. This feels like a set up.           
5. My perception of time is altered.           
6. I feel sleepy           
7. My thoughts are more special or 
significant than usual.           
8. My thoughts or movements seem to 
have a life of their own           
9. I'm worried for my mental or physical 
health           
10. I'm paranoid about the researchers           
11. My perception of objects is altered.           
12. I feel agitated           
13. I'm experiencing profound insights           
14. There is an unusual delay between my 
thinking and speaking.           
15. I'm worried this state of mind won't 
end.           
16. I believe I'm being made a fool of.           
17. Sounds are distorted.           
18. I can't  focus my attention           
19. I can't sustain my concentration           
20. People are are saying things with 
'hidden' or double meanings           
21. I am unsure if I have just been thinking 
a thing or have actually said it out-loud.           
22. I feel I'm making a fool of myself           
23. I believe my mind is being read.           
24. I (or others) can hear my inner thoughts 
outside in external space.           
25. I feel drunk           
26. Currently, events are more significant 
than usual.           
27. My thoughts or movements are being 
controlled by something or somebody else.           
28. This experience is pleasurable.           
29. I feel threatened by the researchers.           
30. My perception of my own body is 
altered.           
 
Table A1.1 The Subjective Experiences of Cannabis Questionnaire (SECQ). Items 













Figure A1.1 The change from baseline in SECQ scores by item, following the 
administration of THC (2.5mg n=3), (1.5mg n=25), (n=1.25mg n=26). The highest 
changes were for ITEM-5 “My perception of time has altered”, ITEM-18 “I can’t 
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Figure A1.2b SECQ-27 (Removal of the following items: sleepy, drunk, pleasurable). 
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Figure A1.3 Change in selected items of the SECQ by dose 
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APPENDIX II: NOTES 
 
2.1 It is important to note that experiencing psychotic symptoms, or being psychotic, 
is not synonymous with ‘having’ schizophrenia. Psychotic symptoms occur, and can 
be the presenting feature, in a long list of medical conditions, which include infections 
(HIV), endocrine disorders (pheochromocytoma), demyelinating disorders (multiple 
sclerosis) and so forth. Further, in contemporary psychiatry there has been a shift 
away from a rigidly categorical approach (mentally-well / mentally-ill) with the 
realization that a percentage of the population will endorse having had schizophrenia-
like psychotic experiences - at some point in their lives, in the absence of functional 
disability - which resolved without treatment.  
 
2.2 Pragmatically, in the world of the psychiatric clinic, such issues are of little 
relevance. Regardless of whether the most prominent psychopathology is in the 
domain of perception, belief or ego-boundaries, the collective term psychosis is 
sufficient. And our current pharmacological treatments do not draw distinctions.  
 
Perhaps one ‘solution’ would be to propose the existence of a “reality-generator”, 
within the CNS. This hypothesized faculty would discriminate the true from the false, 
and mark ‘true’ mental content with the “stamp of reality”. Efficient and proper 
function of this ‘new faculty’ would protect the mind/brain from false perceptions and 
false ideas, whereas failure of this ‘organ’ would be the beginning of psychosis.  
 
Of course the ‘danger’ of such schemes is that over time, what was clearly intended as 
a metaphor (or a model) becomes enshrined as actual truth. For example, it is 
common to encounter talk of “the default mode network”, as if such a faculty actually 
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exists, beyond doubt – on an equal footing for instance with the faculties described by 
William James; attention, concentration, the will and so forth. The ‘slide’ into organ-
isation is complete when the ‘neural correlates’ of  ‘a new faculty/ mental organ’ are 
identified on fMRI brain scans as ‘hot-spots’. 
 
Exploring the organic substrate/correlates of psychosis presents challenges, but these 
are as nothing compared to exploring that substrate within the context of 
schizophrenia: Negative symptoms cognitive deficits, motor symptoms, [all of which 
may or may not be present] fluctuations over time, the progression of some features, 
the diminution of others, add several layers of complexity. The ‘Group of 
Schizophrenias’ emerged from German academic psychiatry, bringing some order to 
the nosological chaos which had been present since [at least] the time of Griesinger 
(1817-1868), but ‘group’ seems to have been relegated to some degree, because it is 
commonplace to hear schizophrenia referred to as if it were a single, well-demarcated 
disease (akin to Huntington’s for example).  
 
2.3 This is a statement of the ‘natural attitude’, certainly for neuroscientists, and 
perhaps even for the majority of psychologists, but as recently as 1994 someone of the 
stature of Francis Crick was required to ‘legitimize’ the idea that brain operations == 
mind operations, in (surely with tongue-in-cheek) “The astonishing Hypothesis” 
Simon & Schuster, London.   
 




The first account postulates the existence of ‘special cells’ at the top of a processing 
hierarchy. These cells are less ‘concerned’ by the raw ‘building blocks’ of sensory 
experience orientation, brightness, colour, pitch etc. Instead, they respond (‘fire’) to 
whole objects (Gestalts), regardless of perspective, illumination and all the other 
idiosyncrasies that make up a perceptual scene. The metaphor of the ‘grandmother 
cell’ captures the idea209. “Each time my grandmother comes into consciousness, via 
any of the sensory channels or in imagination, a ‘special’ cell, somewhere in my 
brain, is active”. The main criticism of the ‘grandmother cell’ hypothesis is that there 
are far more potential percepts, than available neurons. Another criticism is that by 
focusing exclusively on feed-forward pathways, the hypothesis ignores the anatomical 
‘reality’ of extensive feedback pathways. Nevertheless, in-vivo electrophysiological 
work in humans undergoing neurosurgical procedures has provided evidence that 
there are neurons in the medial temporal lobe, which have the characteristics of 
grandmother cells210. 
 
The second account prioritizes flexible, dynamic assemblies of neurons over ‘special’ 
cells. An assembly is defined as a constellation of neurons, which are firing action-
potentials within the same narrow time-window (synchronously). Here, processing is 
a more ‘democratic affair’, and no special cells are required. Feedback and feed-
forward connections are equally important, and the network (the assembly) reaches a 
consensus. Assemblies are transient entities, emerging for a period before 
‘dissolving’, perhaps to ‘reappear’ at a later instant. A temporarily ‘dominant’ 
assembly may ‘recruit’ other ‘partners’. Allegiances are flexible, with co-operation at 
one instant and competition at another. And over longer periods of time, assemblies 
can become – stronger; by virtue of sheer repetition and the ‘rules’ of long-term-
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potentiation (LTP), particularly if monoamine systems are co-active - or weaker; if 
the ‘content’ is fleeting or insignificant.  Oscillations (rhythms) provide a timing 
device, to ensure that the right cells fire at the right time. The individual cells within 
the network give rise to the rhythm, but are themselves constrained by the rhythm119. 
Synchronized gamma (30–200 Hz) rhythms ‘bind’ local assemblies, whereas lower 




2.5 One effect of the interest in rhythms/oscillations was the ‘resurrection’ of 
moribund technology, specifically EEG. The ‘sister’ technology MEG 
magnetoencephalography, was (until recently) virtually unheard of outside Finland, 
Germany and the USA. MEG is new and expensive but offers little advantage over 
EEG aside from less ‘spatial smearing’ of the magnetic compared to the electrical 
signal. MEG also has issues around the head having to remain still etc. For both 
technologies, the ‘inverse problem’ applies: Of the potentially infinite number of 
solutions that account for measurements made at the scalp, which one is correct?  
 
The temporal resolution of EEG/MEG far surpasses that from any other 
‘neuroimaging’ modality. Recording at >1000Hz is routine, meaning that EEG/MEG 
can resolve events in the same timescale within which neuronal tissue operates (i.e. 
the millisecond range).   
 
The temporal resolution of functional MRI imaging approaches 1-2 seconds. 
Although the novelty-value has long faded, fMRI still produces the most eye-catching 
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‘pictures’, if PET is not included in the list.  Leaving aside the debate about whether 
BOLD fMRI represents vascular responses or neural-activation, the more troubling 
issue, the philosophical issue, is that the mind seems to be just too fast to be ‘caught’ 
on an fMRI camera.  
 
There is another philosophical issue, which is better known. This is the phrenology 
charge. Because the BOLD technique involves subtraction of scans under one 
condition from scans under another condition, it always produces a localised signal, 
perhaps a hot spot here or a cold spot there [or in the hands of the un-checked 
beginner, a multitude of hot and cold spots]. It is a ‘phrenological’ method from the 
outset, so it is not at all surprising to obtain ‘phrenological’ solutions.  
 
Of course it would be absurd to argue that one technology is better than another. This 
would be like (amateur) astronomers arguing over whether an X-ray telescope is 
better than a radio telescope for viewing the heavens.  
 
2.6 The story started with oscillations and the precise temporal organisation of spikes 
(action-potentials), but now encompasses ‘phase precession’ and other exotic 
phenomena such as spike-timing-dependent-plasticity (STDP).  
 
Spike-timing-dependent plasticity (STDP) depends on the conjunction of pre and 
post-synaptic events, within a narrow time envelope, of the order of tens of 
milliseconds or so. In the most straightforward version, a synapse is strengthened if a 
pre-synaptic input occurs immediately prior to a post-synaptic action potential (AP). 
If on the other hand, the input arrives in the immediate aftermath of a post-synaptic 
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AP, the synapse is weakened. Pre and post-synaptic events beyond the critical time-
window (i.e. unpaired ‘events’) leave synaptic strength unchanged214.  
 
Four aspects of STDP are notable124:  
- Unlike ‘conventional plasticity, STDP can be evoked without the need for high 
intensity pre-synaptic ‘blasts’ (at 50-100Hz), which rarely occur in ‘normal’ 
physiology. Instead one or two pre and post-synaptic spikes suffice. Timing is the 
critical variable. Energy requirements are kept low.  
 
- Conventional neuromodulators appear to ‘tweak’ STDP. Actually ‘tweak’ is an 
understatement. The presence of a modulator such as dopamine can transform a 
normal pre-> post strengthening into a depression instead. More succinctly, dopamine 
can determine the direction of plasticity (+ or -). 
 
- The critical time window of STDP (tens of milliseconds) is in exactly the same 
‘ballpark’ as network oscillations in the gamma band (period ~25ms).  
 
- Endocannabinoids mediate spike-timing dependent LTD. 
 
2.7 Part of the difficulty is that we are accustomed to talking about the brain as if its 
operations can be described by linear cause-effect relationships. This is common in 
cognitive psychology, but also in ‘biological’ psychiatry. (Think of the ubiquitous box 
and arrow diagram). The term ‘complex’ usually appears at some point, (not to 
signify that things are difficult to understand), but in acknowledgement that a linear 
‘geometry’ is insufficient to capture the operations of the CNS. 
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2.8 It is unclear why stimulant psychosis requires repeated dosing rather than a single 
exposure to the drug215, 216.  At least in healthy participants, the acute effects of 
stimulants are quite unlike paranoid psychoses. According to Freud, “Cocaine brings 
about an exhilaration and lasting euphoria which in no way differs from the normal 
euphoria of the healthy person…You perceive an increase of self-control and possess 
more vitality and capacity for work…In other words you are simply normal, and it is 
soon hard to believe that you are under the influence of any drug. Jones E The life 
and work of Sigmund Freud Basic Books: New-York 1953.” 
Since repeated dosing appears to be a pre-requisite, an adaptive CNS process may be 
involved in the neuropsychiatric sequelae of stimulants117, 217-219.   
 
One of the outcomes of repeated stimulant administration is a functional up-regulation 
of striatal CB1 receptors220. Furthermore, several recent studies have shown that either 
CB1 knockout or blockade of CB1 receptors by potent CB1 antagonists impairs 
stimulant sensitization221-223. In a particularly elegant design it was demonstrated that 
microinjections of a potent CB1 antagonist directly into the ventral striatum reduced 
the expression of behavioral sensitization to methamphetamine117. Findings with the 
first generation CB1 blocker rimonabant in sensitization paradigms have been 
inconsistent223, 224, but rimonabant, as opposed to newer CB1 antagonists, only 
partially blocks the effects of THC in humans126, 225 (Huestis et al., 2001; Zuurman et 
al., 2010) which might explain why an early trial of rimonabant in schizophrenia 
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